{ "version": "2.2", "instance": { "phat-20260630.htm": { "nsprefix": "phat", "nsuri": "http://www.phathompharma.com/20260630", "dts": { "inline": { "local": [ "phat-20260630.htm" ] }, "schema": { "local": [ "phat-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] } }, "keyStandard": 253, "keyCustom": 97, "axisStandard": 24, "axisCustom": 1, "memberStandard": 22, "memberCustom": 51, "hidden": { "total": 11, "http://fasb.org/us-gaap/2026": 7, "http://xbrl.sec.gov/dei/2026": 4 }, "contextCount": 206, "entityCount": 1, "segmentCount": 73, "elementCount": 795, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 577, "http://xbrl.sec.gov/dei/2026": 30, "http://xbrl.sec.gov/ecd/2026": 4 }, "report": { "R1": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "75000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "longName": "75010 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "longName": "75020 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited", "longName": "75030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:GrossProfit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R5": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited", "longName": "75050 - Statement - Condensed Statements of Stockholders' Deficit (Unaudited)", "shortName": "Condensed Statements of Stockholders' Deficit (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_3766f6fd-bd26-4bfc-9f4f-81d025327e72", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d74d05fc-3165-4894-8235-ab58f0a22766", "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R6": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "longName": "75060 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "longName": "995455 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetails", "longName": "995465 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:ComponentOfBalanceSheetDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995475 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitments", "longName": "995485 - Disclosure - Lease Commitments", "shortName": "Lease Commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebt", "longName": "995495 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiability", "longName": "995505 - Disclosure - Revenue Interest Financing Liability", "shortName": "Revenue Interest Financing Liability", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:RevenueInterestFinancingLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:RevenueInterestFinancingLiabilityTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995515 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognition", "longName": "995525 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformation1", "longName": "995535 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuring1", "longName": "995545 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995565 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:OrganizationPolicyTextBlcok", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:OrganizationPolicyTextBlcok", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables", "longName": "995585 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsTables", "longName": "995595 - Disclosure - Lease Commitments (Tables)", "shortName": "Lease Commitments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtTables", "longName": "995605 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables", "longName": "995615 - Disclosure - Revenue Interest Financing Liability (Tables)", "shortName": "Revenue Interest Financing Liability (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "longName": "995625 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionTables", "longName": "995635 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationTables", "longName": "995645 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringTables", "longName": "995655 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995665 - Disclosure - Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "shortName": "Organization, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_6c9e80df-c18d-494f-b3d5-1e031dc40cdb", "name": "phat:NetProceedsAfterDeductingUnderwritersCommission", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R29": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "longName": "995675 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Details)", "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:AccruedEmployeeBenefitsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "longName": "995685 - Disclosure - Balance Sheet Details - Schedule of Inventory (Details)", "shortName": "Balance Sheet Details - Schedule of Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "phat:ComponentOfBalanceSheetDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "longName": "995695 - Disclosure - Commitments and Contingencies - Additional Information (Details)", "shortName": "Commitments and Contingencies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:CommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "phat:PurchaseCommitmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R32": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails", "longName": "995705 - Disclosure - Lease Commitments - Additional Information (Details)", "shortName": "Lease Commitments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "longName": "995715 - Disclosure - Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)", "shortName": "Lease Commitments - Summary of Future Annual Minimum Lease Payments Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails", "longName": "995735 - Disclosure - Debt - Schedule of Total Debt (Details)", "shortName": "Debt - Schedule of Total Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:LongTermDebtCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "longName": "995745 - Disclosure - Debt - Additional Information (Details)", "shortName": "Debt - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_17a01a88-fdf7-4812-a0dd-d6b659903292", "name": "phat:DebtInstrumentFinancialConvenantMinimumCashPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "div", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R36": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails", "longName": "995755 - Disclosure - Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)", "shortName": "Debt - Schedule of Future Minimum Principal and Interest Payments Under Term Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "phat:LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "longName": "995765 - Disclosure - Revenue Interest Financing Liability - Additional Information (Details)", "shortName": "Revenue Interest Financing Liability - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "phat:RevenueInterestFinancingLiabilityTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:InvestorsRightToReceiveRoyaltiesTerminationDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "phat:RevenueInterestFinancingLiabilityTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails", "longName": "995775 - Disclosure - Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)", "shortName": "Revenue Interest Financing Liability - Schedule of Total Revenue Interest Financing Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "phat:RevenueInterestFinancingLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:RoyaltyPaymentsAndPayables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R39": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "longName": "995785 - Disclosure - Stockholders' Equity - Additional Information (Details)", "shortName": "Stockholders' Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_6c9e80df-c18d-494f-b3d5-1e031dc40cdb", "name": "phat:NetProceedsAfterDeductingUnderwritersCommission", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R40": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "longName": "995795 - Disclosure - Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)", "shortName": "Stockholders' Equity - Summary of Common Stock Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_9ebd7c77-b5cb-4212-8010-a1121699fa04", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e5f1355b-0a19-44d9-90ed-09a997189304", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "phat:CommonStockReservedForFutureIssuancesTableTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R41": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "longName": "995805 - Disclosure - Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)", "shortName": "Stockholders' Equity - Summary of PSU and RSUs Activity Under the 2019 Incentive Award Plan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_18701b32-6f3a-4067-a370-1b7a8f44c00c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_18701b32-6f3a-4067-a370-1b7a8f44c00c", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "longName": "995815 - Disclosure - Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)", "shortName": "Stockholders' Equity - Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_9d26726c-5dc2-46ba-b2f7-67239c824ac6", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": null }, "R43": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails", "longName": "995825 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)", "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "phat:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R44": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails", "longName": "995835 - Disclosure - Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "shortName": "Stockholders' Equity - Summary of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_030933f7-809f-4973-9acf-e957fe5f8636", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R45": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "longName": "995845 - Disclosure - Revenue Recognition - Additional Information (Details)", "shortName": "Revenue Recognition - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_aa65e227-3e49-45bd-b594-259cc8435697", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R46": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "longName": "995855 - Disclosure - Revenue Recognition - Summary of Revenue Allowances and Related Accruals (Details)", "shortName": "Revenue Recognition - Summary of Revenue Allowances and Related Accruals (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "us-gaap:ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "phat:SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "995865 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_434b7f83-700d-4e4d-9e3a-15b057ee8469", "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "longName": "995875 - Disclosure - Segment Information - Schedule of Segment Reporting Financial Information (Details)", "shortName": "Segment Information - Schedule of Segment Reporting Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_c2d4be9a-cec5-491d-b6ce-746cc9c11f4f", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8628a85d-2f28-4b4f-a39b-e23d91e13128", "name": "us-gaap:Revenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "unique": true } }, "R49": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "longName": "995885 - Disclosure - Restructuring - Additional Information (Details)", "shortName": "Restructuring - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_dc77e330-3200-4241-b9e6-c721ee5e4d28", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "U_Employee", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_dc77e330-3200-4241-b9e6-c721ee5e4d28", "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated", "unitRef": "U_Employee", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails", "longName": "995895 - Disclosure - Restructuring - Summary of Activity Related to Restructuring Accrual (Details)", "shortName": "Restructuring - Summary of Activity Related to Restructuring Accrual (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f144763b-b9fb-4797-a0cb-4a81ac1d0afb", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "phat-20260630.htm", "first": true, "unique": true } } }, "tag": { "phat_ATMOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ATMOfferingProgramMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "At-the-market offering program.", "label": "A T M Offering Program [Member]", "terseLabel": "At-the-Market Offering Program" } } }, "auth_ref": [] }, "us-gaap_AccountingStandardsUpdate202006Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingStandardsUpdate202006Member", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ASU 2020-06", "label": "Accounting Standards Update 2020-06 [Member]", "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity." } } }, "auth_ref": [ "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "verboseLabel": "Accounts payable, related parties", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r873", "r1001", "r1005" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsReceivableMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r775", "r1096" ] }, "phat_AccruedClinicalTrialExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedClinicalTrialExpensesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Accrued clinical trial expenses current.", "label": "Accrued Clinical Trial Expenses Current", "terseLabel": "Accrued clinical trial expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedEmployeeBenefitsCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued compensation expenses", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1006" ] }, "phat_AccruedExpensesRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedExpensesRelatedPartiesCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Accrued expenses related parties current.", "label": "Accrued Expenses Related Parties Current", "terseLabel": "Accrued expenses, related parties" } } }, "auth_ref": [] }, "phat_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedInterest", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued interest.", "label": "Accrued Interest", "terseLabel": "Accrued interest" } } }, "auth_ref": [] }, "phat_AccruedInterestOnRevenueInterestFinancingLiabilityNetOfPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedInterestOnRevenueInterestFinancingLiabilityNetOfPayments", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Accrued Interest On Revenue Interest Financing Liability Net Of Payments", "documentation": "Accrued interest on revenue interest financing liability net of payments.", "terseLabel": "Accrued interest on revenue interest financing liability, net of payments" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1006" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "phat_AccruedPayment-In-KindInterestOnDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedPayment-In-KindInterestOnDebt", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued payment-in-kind interest on debt", "label": "Accrued Payment-In-Kind Interest On Debt", "documentation": "Accrued payment-in-kind interest on debt." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional & consulting expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r1006" ] }, "phat_AccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedResearchAndDevelopmentExpenses", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Accrued research and development expenses.", "label": "Accrued Research And Development Expenses", "terseLabel": "Accrued research and development expenses" } } }, "auth_ref": [] }, "phat_AccruedRevenueAllowancesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AccruedRevenueAllowancesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued revenue allowances", "label": "Accrued Revenue Allowances Current", "documentation": "Accrued revenue allowances current." } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Royalty expense included in accrued expenses", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r796", "r1006" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r940" ] }, "phat_AdditionalFundingAchievementOfSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AdditionalFundingAchievementOfSalesMilestone", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional funding achievement of sales milestone.", "label": "Additional Funding Achievement Of Sales Milestone", "terseLabel": "Additional funding achievement of sales milestone" } } }, "auth_ref": [] }, "phat_AdditionalFundingAvailable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AdditionalFundingAvailable", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additional Funding Available", "documentation": "Additional funding available.", "terseLabel": "Additional funding available" } } }, "auth_ref": [] }, "phat_AdditionalLoanTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AdditionalLoanTrancheMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Additional Loan Tranche [Member]", "documentation": "Additional loan tranche.", "terseLabel": "Additional Loan Tranche" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r1015", "r1149" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r641", "r700", "r1088", "r1089", "r1090", "r1092", "r1193", "r1276" ] }, "phat_AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AdditionalPercentageToBePaidWithObligatedPaymentOnInvestmentAmount", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional percentage to be paid with obligated payment on investment amount", "label": "Additional Percentage to be Paid with Obligated Payment On Investment Amount", "documentation": "Additional percentage to be paid with obligated payment on investment amount." } } }, "auth_ref": [] }, "phat_AdditionalWarrantIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AdditionalWarrantIssued", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Additional warrant issued.", "label": "Additional Warrant Issued", "terseLabel": "Additional warrant issued" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r953" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r953" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r953" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r953" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r58", "r59", "r60", "r61", "r62", "r63", "r119", "r120", "r121", "r145", "r146", "r147", "r148", "r149", "r150", "r160", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r330", "r331", "r332", "r333", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r433", "r434", "r435", "r436", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r528", "r558", "r559", "r560", "r561", "r562", "r563", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r397" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Adjustments to additional paid in capital, warrant issued", "verboseLabel": "Pre-funded warrants amount allocated to additional paid-in capital", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r12", "r1145", "r1150", "r1151" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdvertisingCostsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising and Marketing Costs", "documentation": "Disclosure of accounting policy for advertising cost." } } }, "auth_ref": [ "r48" ] }, "phat_AggregateOfferingPriceThroughEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AggregateOfferingPriceThroughEquityFinancing", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price through equity financing.", "label": "Aggregate offering price through equity financing", "terseLabel": "Aggregate offering price through equity financing" } } }, "auth_ref": [] }, "phat_AggregatePaymentsOnInvestmentAmountToInvestor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AggregatePaymentsOnInvestmentAmountToInvestor", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate payments made to investors", "label": "Aggregate Payments On Investment Amount To Investor", "documentation": "Aggregate Payments On Investment Amount To Investor" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r986" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r915", "r925", "r935", "r967" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r987" ] }, "phat_AgreementExpirationTermFromDateOfFirstCommercialSale": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AgreementExpirationTermFromDateOfFirstCommercialSale", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Agreement expiration term from date of first commercial sale.", "label": "Agreement Expiration Term From Date Of First Commercial Sale", "terseLabel": "Agreement expiration term from date of first commercial sale" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r953" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r960" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r916", "r926", "r936", "r960", "r968", "r972", "r980" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r978" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation cost", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r427", "r437", "r438" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "phat_AmendmentToFifthLoanAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AmendmentToFifthLoanAmendmentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Amendment to Fifth Loan Amendment [Member]", "documentation": "Amendment to fifth loan amendment.", "terseLabel": "Amendment to Fifth Loan Amendment" } } }, "auth_ref": [] }, "phat_AmendmentToLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AmendmentToLoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment to Loan Agreement", "label": "Amendment to Loan Agreement [Member]", "documentation": "Amendment to loan agreement." } } }, "auth_ref": [] }, "phat_AmendmentToWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AmendmentToWarrantsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment to Warrants", "label": "Amendment to Warrants [Member]", "documentation": "Amendment to warrants." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt discount", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r25", "r321", "r1079", "r1206" ] }, "phat_AmountUtilizedOfEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AmountUtilizedOfEquityFinancing", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount Utilized of equity financing.", "terseLabel": "Amount utilized of equity financing", "label": "Amount Utilized of equity financing" } } }, "auth_ref": [] }, "phat_AnneMarieCookMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AnneMarieCookMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Anne Marie Cook [Member]", "documentation": "Anne Marie Cook." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested shares excluded from computation of weighted average earnings per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "verboseLabel": "Weighted-average unvested shares", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r168" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r168" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r168" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r475" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r68", "r69", "r82", "r131", "r134", "r135", "r171", "r184", "r209", "r213", "r223", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r477", "r481", "r531", "r619", "r620", "r621", "r634", "r635", "r643", "r729", "r822", "r823", "r841", "r873", "r890", "r891", "r903", "r1140", "r1141", "r1215" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r68", "r69", "r107", "r131", "r134", "r135", "r223", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r477", "r481", "r531", "r873", "r997", "r1140", "r1141", "r1215" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "phat_AtTheMarketOfferingSharesForNetProceeds": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AtTheMarketOfferingSharesForNetProceeds", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "At the Market Offering Shares for Net Proceeds", "label": "At the Market Offering Shares for Net Proceeds", "terseLabel": "At the market offering shares for net proceeds" } } }, "auth_ref": [] }, "phat_AvailableAggregateOfferingPriceThroughEquityFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "AvailableAggregateOfferingPriceThroughEquityFinancing", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available equity financing amount", "label": "Available Aggregate offering price through equity financing", "documentation": "Available Aggregate offering price through equity financing." } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r975" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r976" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r971" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r424", "r425", "r426" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r974" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r973" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r972" ] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BaseRateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Floor Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [ "r1002", "r1007", "r1139" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r1081" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment purchases included in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r1080" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalent", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r80", "r126", "r130", "r792", "r1217" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r127" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodEndLabel": "Cash and cash equivalents and restricted cash - end of period", "periodStartLabel": "Cash and cash equivalents and restricted cash - beginning of period", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r30", "r126", "r130" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation", "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r30" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of noncash investing and financing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "terseLabel": "Accounting Standards Update, Adopted", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth_ref": [ "r58", "r59", "r63", "r119", "r145", "r228", "r230", "r246", "r255", "r330", "r380", "r385", "r433", "r454", "r457", "r465", "r470", "r488", "r500", "r501", "r507", "r508", "r528", "r558", "r559", "r679", "r680" ] }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date", "terseLabel": "Accounting Standards Update, Adopted Date", "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format." } } }, "auth_ref": [ "r58", "r59", "r60", "r119", "r228", "r229", "r230", "r231", "r246", "r247", "r255", "r330", "r331", "r380", "r381", "r385", "r386", "r433", "r434", "r454", "r457", "r465", "r466", "r470", "r471", "r488", "r489", "r500", "r501", "r502", "r507", "r508", "r509", "r512", "r528", "r558", "r559", "r679", "r680", "r993", "r1091" ] }, "phat_ChangeInControlDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ChangeInControlDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in control description", "label": "Change in Control Description", "documentation": "Change in control description." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r951" ] }, "phat_ChargesForInventoryNotExpectedToBeSoldPriorToItsExpirationDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ChargesForInventoryNotExpectedToBeSoldPriorToItsExpirationDate", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges for inventory not expected to be sold prior to its expiration date", "label": "Charges For Inventory Not Expected To Be Sold Prior To Its Expiration Date", "documentation": "Charges for inventory not expected to be sold prior to its expiration date." } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r948" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r946" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r1146" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [ "r1146" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Warrants exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r131", "r136", "r347" ] }, "phat_ClassOfWarrantOrRightExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ClassOfWarrantOrRightExpirationDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, expiration date.", "label": "Class of Warrant or Right Expiration Date", "terseLabel": "Warrants expiration date" } } }, "auth_ref": [] }, "phat_ClassOfWarrantOrRightExpireTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ClassOfWarrantOrRightExpireTerm", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, expire term.", "label": "Class of Warrant or Right Expire Term", "terseLabel": "Warrants expire term" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Outstanding warrants issued to purchase shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Warrants issued to purchase shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r1146" ] }, "phat_ClassOfWarrantsPurchasePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ClassOfWarrantsPurchasePricePerShare", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrants purchase price per share.", "label": "Class Of Warrants Purchase Price Per Share", "terseLabel": "Warrants purchase price" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r952" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r952" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Liability [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r475" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 3)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r97", "r619", "r620", "r625", "r645", "r716" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r282", "r283", "r776", "r1127", "r1134", "r1136" ] }, "phat_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "auth_ref": [] }, "phat_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "verboseLabel": "Common stock reserved for future issuance (in shares)", "terseLabel": "Common stock initially reserved for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r1146" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r101", "r353", "r619", "r620", "r628", "r893", "r894", "r895", "r897", "r898", "r899", "r900", "r1088", "r1089", "r1092", "r1193", "r1273", "r1276" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r1014", "r1148", "r1223", "r1224", "r1228" ] }, "phat_CommonStockReservedForFutureIssuancesTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CommonStockReservedForFutureIssuancesTableTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Common stock reserved for future issuances.", "label": "Common Stock Reserved For Future Issuances Table Table [Text Block]", "terseLabel": "Summary of Common Stock Reserved for Future Issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, authorized shares", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, authorized shares", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r353", "r619", "r620", "r628", "r717" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares", "verboseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r101", "r353", "r619", "r620", "r628" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares", "terseLabel": "Common stock, outstanding shares", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r101", "r353", "r619", "r620", "r628", "r717", "r735", "r1145", "r1276", "r1277" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; authorized shares -400,000,000 at June 30, 2026 and December 31, 2025; issued and outstanding shares - 80,070,048 and 71,419,025 at June 30, 2026 and December 31, 2025, respectively", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock fair value", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r101", "r335", "r341", "r353", "r619", "r620", "r628", "r647", "r873" ] }, "phat_CommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CommonStockWarrantMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Common stock warrants.", "label": "Common Stock Warrant [Member]", "terseLabel": "Common Stock Warrants including Pre-Funded Warrants", "verboseLabel": "Common Stock Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r957" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r956" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r958" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r955" ] }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CompensationRelatedCostsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Compensation Related Costs, Policy [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense." } } }, "auth_ref": [ "r36", "r39" ] }, "phat_ComponentOfBalanceSheetDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ComponentOfBalanceSheetDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetails" ], "lang": { "en-us": { "role": { "documentation": "Component of Balance Sheet Disclosure.", "label": "Component Of Balance Sheet Disclosure [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "phat_ComputerEquipmentAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ComputerEquipmentAndSoftwareMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Computer equipment and software.", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment and Related Software" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r174", "r221", "r692", "r693", "r775", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r174", "r221", "r692", "r693", "r775", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r174", "r221", "r692", "r693", "r775", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument." } } }, "auth_ref": [ "r529", "r530" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration of risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r174", "r221", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r174", "r221", "r692", "r693", "r775", "r1095", "r1096", "r1097", "r1098", "r1099" ] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityAbstract", "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of revenue interest financing liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r364", "r365", "r368", "r378", "r795" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Revenue interest financing liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r364", "r365", "r368", "r378" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Receivable, after Allowance for Credit Loss, Total", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "periodStartLabel": "Balance as of January 1, 2026", "periodEndLabel": "Balance as of June 30, 2026", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r364", "r366", "r368", "r378", "r774" ] }, "phat_ContractWithCustomerReceivableAllowanceForCreditLossAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ContractWithCustomerReceivableAllowanceForCreditLossAccruals", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Receivable, Allowance for Credit Loss, Accruals", "documentation": "Contract with customer, receivable, allowance for credit loss, accruals.", "terseLabel": "Accruals" } } }, "auth_ref": [] }, "phat_ContractWithCustomerReceivableAllowanceForCreditLossUtilizations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ContractWithCustomerReceivableAllowanceForCreditLossUtilizations", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Receivable, Allowance for Credit Loss, Utilizations", "documentation": "Contract with customer, receivable, allowance for credit loss, utilizations.", "terseLabel": "Utilizations", "negatedLabel": "Utilizations" } } }, "auth_ref": [] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 1.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of Revenue, Total", "label": "Cost of Revenue", "terseLabel": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r20", "r131", "r134", "r135", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r531", "r822", "r995", "r996", "r1118", "r1140" ] }, "phat_CostOfRevenuePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CostOfRevenuePolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Cost of Revenue [Policy Text Block]", "label": "Cost of Revenue [Policy Text Block]", "terseLabel": "Cost of Revenue" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r131", "r139", "r140", "r303", "r345", "r567", "r570", "r580", "r642", "r801", "r802", "r803", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1188", "r1189", "r1190", "r1191", "r1218", "r1219" ] }, "phat_CovenantExtensionAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CovenantExtensionAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Covenant extension amendment fee", "label": "Covenant extension amendment fee", "documentation": "Covenant extension amendment fee." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r221", "r1096" ] }, "phat_CustomerCreditsDiscountsAndAllowanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "CustomerCreditsDiscountsAndAllowanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Customer Credits, Discounts and Allowance [Member]", "documentation": "Customer credits, discounts and allowance.", "terseLabel": "Customer Credits, Discounts and Allowances" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r35", "r78", "r79", "r84", "r85", "r88", "r90", "r91", "r93", "r94", "r131", "r133", "r264", "r265", "r266", "r267", "r268", "r288", "r289", "r299", "r305", "r306", "r307", "r308", "r309", "r310", "r315", "r322", "r323", "r325", "r487", "r541", "r619", "r620", "r624" ] }, "phat_DebtInstrumentAdditionalBorrowingCapacityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentAdditionalBorrowingCapacityAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument additional borrowing capacity amount.", "label": "Debt Instrument Additional Borrowing Capacity Amount", "terseLabel": "Debt instrument, additional borrowing capacity amount" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r78", "r79", "r84", "r88", "r89", "r90", "r91", "r92", "r94", "r300", "r301", "r302", "r303", "r304", "r306", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r347", "r619", "r620", "r624", "r836", "r837", "r838", "r839", "r840", "r871", "r1082", "r1083", "r1084", "r1087", "r1128", "r1129", "r1130", "r1205", "r1207", "r1229" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt outstanding", "totalLabel": "Total term loan borrowings", "verboseLabel": "Term loans aggregate principal amount", "label": "Aggregate principal amount", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r326", "r1223", "r1224", "r1226" ] }, "phat_DebtInstrumentCovenantAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentCovenantAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant [Axis]", "documentation": "Debt instrument covenant axis." } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantComplianceCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentCovenantComplianceCommitmentAmount", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Compliance Commitment Amount", "documentation": "Debt Instrument Covenant Compliance Commitment Amount", "terseLabel": "Minimum Cash Covenant, Amount" } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantCompliancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentCovenantCompliancePercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant Compliance Percentage", "documentation": "Debt instrument covenant compliance percentage.", "terseLabel": "Minimum Cash Covenant, Percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentCovenantDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentCovenantDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Covenant [Domain]", "documentation": "Debt instrument covenant domain" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate amount of debt instrument", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r300", "r541", "r542", "r837", "r838", "r871" ] }, "phat_DebtInstrumentFacilityChargePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFacilityChargePercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument facility charge percentage.", "label": "Debt Instrument Facility Charge Percentage", "terseLabel": "Debt instrument, facility charge percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentFacilityFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFacilityFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Facility fee", "label": "Debt Instrument Facility Fee", "documentation": "Debt instrument facility fee." } } }, "auth_ref": [] }, "phat_DebtInstrumentFinalPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFinalPaymentFee", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Final Payment Fee", "documentation": "Debt instrument final payment fee.", "verboseLabel": "Debt instrument, final payment fee or end of term charge", "terseLabel": "Less: final payment fees", "negatedLabel": "Less: final payment fees" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinalPaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFinalPaymentFeePercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument final payment fee percentage.", "label": "Debt Instrument Final Payment Fee Percentage", "terseLabel": "Debt instrument, final payment fee percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantMinimumCashPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFinancialConvenantMinimumCashPercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Minimum Cash Convenant Percentage.", "label": "Debt Instrument Financial Convenant Minimum Cash Percentage", "terseLabel": "Financial convenants, Minimum cash convenant" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantsPercentageOfProjectedRevenue": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFinancialConvenantsPercentageOfProjectedRevenue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Financial Convenants Percentage of Projected Revenue.", "label": "Debt Instrument Financial Convenants Percentage of Projected Revenue", "terseLabel": "Financial covenants, Projected revenue percentage" } } }, "auth_ref": [] }, "phat_DebtInstrumentFinancialConvenantsProjectedRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentFinancialConvenantsProjectedRevenue", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Financial Convenants Projected Revenue", "label": "Debt Instrument Financial Convenants Projected Revenue", "terseLabel": "Financial convenants, Projected revenue" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Debt instrument, interest rate percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r328", "r541", "r542", "r871", "r1002", "r1007", "r1223", "r1224", "r1226" ] }, "phat_DebtInstrumentInterestRatePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentInterestRatePercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument, interest rate percentage.", "label": "Debt Instrument, Interest Rate Percentage", "terseLabel": "Debt instrument interest rate" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt instrument, interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r79", "r88", "r301", "r619", "r620", "r624" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r79", "r88", "r89", "r90", "r91", "r92", "r94", "r300", "r301", "r302", "r303", "r304", "r306", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r347", "r487", "r619", "r620", "r624", "r638", "r836", "r837", "r838", "r839", "r840", "r871", "r1082", "r1083", "r1084", "r1087", "r1205", "r1207" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r79", "r89", "r619", "r620", "r624", "r836", "r1197", "r1198" ] }, "phat_DebtInstrumentMinimumPerDrawAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentMinimumPerDrawAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument minimum per draw amount.", "label": "Debt Instrument Minimum Per Draw Amount", "terseLabel": "Debt instrument minimum per draw amountd" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r78", "r79", "r84", "r88", "r89", "r90", "r91", "r92", "r94", "r300", "r301", "r302", "r303", "r304", "r306", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r347", "r619", "r620", "r624", "r836", "r837", "r838", "r839", "r840", "r871", "r1082", "r1083", "r1084", "r1087", "r1128", "r1129", "r1130", "r1205", "r1207", "r1229" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentPaymentTerms", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt instrument, description", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r18", "r1002", "r1008" ] }, "phat_DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentPrepaymentFeePercentageOfOutstandingPrincipalAmount", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument prepayment fee percentage of outstanding principal amount.", "label": "Debt Instrument Prepayment Fee Percentage Of Outstanding Principal Amount", "terseLabel": "Debt instrument, prepayment fee percentage of outstanding principal amount" } } }, "auth_ref": [] }, "phat_DebtInstrumentPrepaymentFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentPrepaymentFees", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Prepayment Fees", "documentation": "Debt instrument prepayment fees.", "terseLabel": "Debt instrument prepayment fees" } } }, "auth_ref": [] }, "phat_DebtInstrumentPrincipalRepaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtInstrumentPrincipalRepaymentPercentage", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Principal Repayment Percentage", "documentation": "Debt instrument principal repayment percentage.", "terseLabel": "Debt instrument, principal repayment percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r17", "r44", "r45", "r46", "r79", "r88", "r89", "r90", "r91", "r92", "r94", "r300", "r301", "r302", "r303", "r304", "r306", "r311", "r312", "r313", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r324", "r347", "r487", "r619", "r620", "r624", "r638", "r836", "r837", "r838", "r839", "r840", "r871", "r1082", "r1083", "r1084", "r1087", "r1205", "r1207" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Unamortized debt discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1143", "r1204", "r1205", "r1207" ] }, "phat_DebtIssuanceCostsAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtIssuanceCostsAmortizationPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs Amortization Period", "documentation": "Debt issuance costs amortization period.", "terseLabel": "Debt issuance costs amortization period" } } }, "auth_ref": [] }, "phat_DebtinstrumentAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtinstrumentAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "DebtInstrument amendment fee.", "label": "DebtInstrument Amendment Fee", "terseLabel": "Debt instrument, Amendment fee" } } }, "auth_ref": [] }, "phat_DebtinstrumentTrailingNetProductRevenuePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DebtinstrumentTrailingNetProductRevenuePeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "DebtInstrument Trailing Net Product Revenue Period.", "label": "DebtInstrument Trailing Net Product Revenue Period", "terseLabel": "Trailing Net Product Revenue, Period" } } }, "auth_ref": [] }, "phat_DefaultObligationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DefaultObligationDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Default obligation description", "label": "Default Obligation Description", "documentation": "Default obligation description." } } }, "auth_ref": [] }, "phat_DeferredDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DeferredDebtIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Debt Issuance Costs", "documentation": "Deferred debt issuance costs.", "terseLabel": "Deferred debt issuance costs" } } }, "auth_ref": [] }, "phat_DeferredDebtIssuanceCostsAndFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DeferredDebtIssuanceCostsAndFees", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred debt issuance costs and fees", "label": "Deferred Debt Issuance Costs and Fees", "documentation": "Deferred debt issuance costs and fees." } } }, "auth_ref": [] }, "phat_DeferredIssuanceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DeferredIssuanceFees", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Issuance Fees", "documentation": "Deferred issuance fees.", "terseLabel": "Deferred issuance fees" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Cost", "terseLabel": "Defined contribution plan employer contribution liabilities expense", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r392" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "401(k) matching contribution", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "phat_DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DefinedContributionPlanEmployerDiscretionaryMatchNumberOfSharesSettled", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Defined contribution pan employer discretionary match number of shares settled.", "label": "Defined Contribution Plan Employer Discretionary Match Number Of Shares Settled", "terseLabel": "401(k) matching contribution, shares", "verboseLabel": "Employer discretionary match number of shares settled" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Defined contribution plan, employer matching contribution, percentage", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "phat_DefinedContributionPlansLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "DefinedContributionPlansLiabilities", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Defined contribution plan liabilities.", "label": "Defined Contribution Plans Liabilities", "terseLabel": "Defined contribution plan liability" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Total", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r3", "r118", "r171", "r189", "r213", "r804", "r822", "r823", "r1119", "r1120", "r1123", "r1125" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r376", "r377", "r843", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r376", "r377", "r843", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r395", "r399", "r428", "r429", "r432", "r851" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r907" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "verboseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r939" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DomesticCountryMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction, Domestic Federal [Member]", "terseLabel": "Domestic", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r444" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r950" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r63", "r115", "r146", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r161", "r163", "r165", "r166", "r167", "r170", "r254", "r333", "r384", "r435", "r463", "r474", "r516", "r517", "r633", "r656", "r811" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r63", "r115", "r146", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r163", "r165", "r166", "r167", "r170", "r254", "r333", "r384", "r435", "r463", "r474", "r516", "r517", "r633", "r656", "r811" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r169" ] }, "phat_EmployeeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeeOneMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee One [Member]", "terseLabel": "Employee One", "documentation": "Employee one." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r1180" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r431" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized stock-based compensation expense, weighted-average period for recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r431" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1181" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1181" ] }, "phat_EmployeeServiceShareBasedCompensationVestedAwardsTotalCompensationCostRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeeServiceShareBasedCompensationVestedAwardsTotalCompensationCostRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Vested Awards Total Compensation Cost Recognized Stock Options", "documentation": "Employee service share based compensation vested awards total compensation cost recognized stock options", "terseLabel": "Recognized stock-based compensation expense vesting" } } }, "auth_ref": [] }, "phat_EmployeeServiceShareBasedCompensationVestedAwardsTotalCompensationCostRecognizedStockOptionsAndMilestonePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeeServiceShareBasedCompensationVestedAwardsTotalCompensationCostRecognizedStockOptionsAndMilestonePrice", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Service Share Based Compensation Vested Awards Total Compensation Cost Recognized Stock Options And Milestone Price", "documentation": "Employee service share based compensation vested awards total compensation cost recognized stock options and milestone price.", "terseLabel": "Stock-based compensation expense upon vesting and milestone price" } } }, "auth_ref": [] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeSeveranceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Employee Severance", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "phat_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeeStockPurchasePlanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan", "verboseLabel": "ESPP Plan" } } }, "auth_ref": [] }, "phat_EmployeeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeeTwoMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee two.", "label": "Employee Two [Member]", "terseLabel": "Employee Two" } } }, "auth_ref": [] }, "phat_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "EmployeesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees [Member]", "terseLabel": "Employees" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r905" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r905" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r990" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "verboseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r905" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r989" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r905" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r905" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r905" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r905" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r944" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r985" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r985" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r985" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquipmentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [ "r1124", "r1125" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r62", "r63", "r74", "r100", "r101", "r111", "r112", "r113", "r142", "r143", "r144", "r147", "r155", "r157", "r159", "r172", "r224", "r227", "r253", "r254", "r256", "r332", "r346", "r351", "r352", "r353", "r356", "r358", "r360", "r382", "r383", "r387", "r388", "r435", "r452", "r453", "r459", "r460", "r461", "r464", "r473", "r474", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r503", "r504", "r505", "r506", "r515", "r535", "r536", "r537", "r538", "r539", "r540", "r544", "r563", "r581", "r619", "r620", "r627", "r628", "r641", "r655", "r681", "r682", "r683", "r700", "r754", "r1152" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r954" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r909", "r919", "r929", "r961" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r960" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r518", "r519", "r520", "r521", "r863", "r1197", "r1202" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of Reconciliation of Liabilities Measured at Fair Value", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r522", "r525", "r527" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r518", "r519", "r520", "r521", "r863", "r1197", "r1202" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [ "r1199", "r1200" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3", "terseLabel": "Fair value liability, transfers into level 3", "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r524", "r526", "r527" ] }, "us-gaap_FairValueMeasurementsNonrecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsNonrecurringMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Nonrecurring [Member]", "terseLabel": "Fair Value, Nonrecurring", "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value." } } }, "auth_ref": [ "r518", "r519", "r520", "r521", "r863", "r1197" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r863", "r1194", "r1195", "r1196", "r1197", "r1198", "r1202" ] }, "phat_FifthLoanAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "FifthLoanAmendmentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Fifth Loan Amendment [Member]", "documentation": "Fifth Loan Amendment.", "terseLabel": "Fifth Loan Amendment" } } }, "auth_ref": [] }, "phat_FinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "FinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Financial assets fair value disclosure.", "label": "Financial Assets Fair Value Disclosure", "terseLabel": "Financial assets fair value disclosure" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ForeignCountryMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Income Tax Jurisdiction, Foreign [Member]", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r444", "r445" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r916", "r926", "r936", "r968" ] }, "phat_FoundersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "FoundersMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Founders.", "label": "Founders [Member]", "terseLabel": "Founders" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r949" ] }, "phat_FrazierLifeSciencesIXLimitedPartnerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "FrazierLifeSciencesIXLimitedPartnerMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Frazier Life Sciences IX, limited partner member.", "label": "Frazier Life Sciences I X Limited Partner [Member]", "terseLabel": "Frazier" } } }, "auth_ref": [] }, "phat_FundsReceivedFromInitialClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "FundsReceivedFromInitialClosing", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Funds received from initial closing", "label": "Funds Received from Initial Closing", "documentation": "Funds received from initial closing." } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [ "r835", "r1124", "r1125" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Extinguishment of Debt", "terseLabel": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r3", "r13", "r14" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "totalLabel": "General and Administrative Expense, Total", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r23", "r738" ] }, "us-gaap_GranteeStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GranteeStatusAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Axis]", "terseLabel": "Grantee Status", "documentation": "Information by status of recipient to whom award is granted." } } }, "auth_ref": [ "r396", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_GranteeStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GranteeStatusDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Grantee Status [Domain]", "terseLabel": "Grantee Status", "documentation": "Status of recipient to whom award is granted." } } }, "auth_ref": [ "r396", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r424", "r425", "r426" ] }, "phat_GrossProceedsFromRevenueInterestFinancingAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "GrossProceedsFromRevenueInterestFinancingAgreement", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Proceeds from the Revenue Interest Financing Agreement", "terseLabel": "Gross proceeds", "label": "Gross Proceeds from Revenue Interest Financing Agreement", "documentation": "Gross proceeds from revenue interest financing agreement." } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r19", "r20", "r131", "r134", "r135", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r531", "r815", "r822", "r995", "r996", "r1094", "r1102", "r1108", "r1111", "r1112", "r1118", "r1140" ] }, "us-gaap_GrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GrossProfitAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]" } } }, "auth_ref": [] }, "phat_HerculesAndSvbTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "HerculesAndSvbTermLoanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Hercules and SVB term loan.", "label": "Hercules and SVB Term Loan [Member]", "terseLabel": "Hercules and SVB Term Loan" } } }, "auth_ref": [] }, "phat_HerculesLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "HerculesLoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hercules Loan Agreement", "label": "Hercules Loan Agreement [Member]", "documentation": "Hercules loan agreement." } } }, "auth_ref": [] }, "phat_HerculesTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "HerculesTermLoanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Hercules Term Loan [Member]", "label": "Hercules Term Loan [Member]", "terseLabel": "Hercules Term Loan" } } }, "auth_ref": [] }, "stpr_IL": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2026", "localname": "IL", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "ILLINOIS", "terseLabel": "Buffalo Grove, Illinois" } } }, "auth_ref": [] }, "phat_IPOAndATMOfferingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "IPOAndATMOfferingsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "IPO and ATM offerings.", "label": "I P O and A T M Offerings [Member]", "terseLabel": "IPO and ATM", "verboseLabel": "IPO And ATM Offerings" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets to be Disposed of", "terseLabel": "Impairment losses", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale." } } }, "auth_ref": [ "r3", "r1031" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Excluding Intangible Asset and Goodwill, Impairment and Disposal [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r1126" ] }, "us-gaap_InProcessResearchAndDevelopmentPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InProcessResearchAndDevelopmentPolicy", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "In Process Research and Development, Policy [Policy Text Block]", "terseLabel": "In-Process Research and Development", "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r129", "r444", "r445", "r446", "r450", "r853", "r1185" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r129", "r444", "r445", "r446", "r450", "r853", "r1185" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r110", "r442", "r443", "r447", "r448", "r449", "r451", "r695" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInInterestPayableNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 21.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventory", "label": "Increase (Decrease) in Inventories", "totalLabel": "Increase (Decrease) in Inventories, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r2" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "phat_IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating right-of-use assets and lease liabilities", "documentation": "Increase (decrease) in operating right of use asset and lease liabilities.", "label": "Increase Decrease In Operating Right Of Use Asset And Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "terseLabel": "Other long-term assets", "negatedLabel": "Other long-term assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r1078" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r2" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r916", "r926", "r936", "r960", "r968", "r972", "r980" ] }, "phat_InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InitialInvestorsAndCoFinanceLVSXXXVIILLCAndHerculesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial investors and co finance lvs xxxvii llc and hercules.", "label": "Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member]", "terseLabel": "Initial Investors And CO Finance L V S X X X V I I L L C And Hercules [Member]" } } }, "auth_ref": [] }, "phat_InitialInvestorsNqSagardAndHerculesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InitialInvestorsNqSagardAndHerculesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial Investors NQ, Sagard, and Hercules", "label": "Initial Investors NQ, Sagard, and Hercules [Member]", "documentation": "Initial Investors NQ, Sagard, and Hercules." } } }, "auth_ref": [] }, "phat_InitialPublicOfferingSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InitialPublicOfferingSharesOfCommonStock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Initial Public Offering Shares of Common Stock", "label": "Initial Public Offering Shares of Common Stock", "terseLabel": "Initial public offering shares of common stock" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r978" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r908", "r984" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r908", "r984" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r908", "r984" ] }, "phat_InterestBearingRateUponCustomaryEvents": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InterestBearingRateUponCustomaryEvents", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Interest bearing rate upon customary events.", "label": "Interest Bearing Rate Upon Customary Events", "terseLabel": "Interest bearing rate upon customary events" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Interest Expense, Debt, Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r25", "r319", "r329", "r839", "r840", "r1275" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Interest Expense, Nonoperating, Total", "label": "Interest Expense, Nonoperating", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r188", "r806", "r809", "r1033" ] }, "phat_InterestExpenseRelatedToRevenueInterestFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InterestExpenseRelatedToRevenueInterestFinancingLiability", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Interest expense with revenue interest finance liability", "terseLabel": "Plus: interest expense", "label": "Interest Expense Related To Revenue Interest Financing Liability", "documentation": "Interest expense related to revenue interest financing liability" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity", "terseLabel": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r122", "r124", "r128" ] }, "us-gaap_InterestPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InterestPayableCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Interest Payable, Current", "terseLabel": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r799" ] }, "us-gaap_InventoryAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryAdjustments", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory adjustments", "label": "Inventory Adjustments", "totalLabel": "Inventory Adjustments, Total", "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods." } } }, "auth_ref": [ "r10", "r999", "r1018" ] }, "phat_InventoryCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InventoryCurrentAndNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "documentation": "Inventory current and noncurrent.", "label": "Inventory Current and Noncurrent", "totalLabel": "Total inventory" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r34", "r798", "r800" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "phat_InventoryCurrentAndNoncurrent", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net", "totalLabel": "Total inventory, current", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r76", "r106", "r793", "r873" ] }, "us-gaap_InventoryNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Inventory, Noncurrent, Total", "label": "Inventory, Noncurrent", "terseLabel": "Inventory, non-current", "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle." } } }, "auth_ref": [ "r1000", "r1004" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r47", "r73", "r76", "r105", "r232", "r233", "r235", "r583", "r810" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r999", "r1016" ] }, "phat_InventoryRawMaterialsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InventoryRawMaterialsNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails": { "parentTag": "phat_InventoryCurrentAndNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfInventoryDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials, non-current", "documentation": "Inventory raw materials noncurrent.", "label": "Inventory Raw Materials Noncurrent" } } }, "auth_ref": [] }, "us-gaap_InventoryStatedAboveCost": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryStatedAboveCost", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Stated Above Cost [true false]", "documentation": "Indicates (true false) whether inventory is stated above cost." } } }, "auth_ref": [ "r53" ] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InventoryWriteDown", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventory reserve", "label": "Inventory Write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r234" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "negatedLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r171", "r187", "r213", "r822", "r1032" ] }, "phat_InvestorAdditionalFundingAmountUponApproval": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InvestorAdditionalFundingAmountUponApproval", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors additional funding amount upon FDA approval of vonoprazan for treatment of erosive esophagitis", "documentation": "Investor additional funding amount upon approval.", "label": "Investor Additional Funding Amount Upon Approval" } } }, "auth_ref": [] }, "phat_InvestorsFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InvestorsFundingAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Investors funding amount.", "label": "Investors Funding Amount", "terseLabel": "Investors funding amount" } } }, "auth_ref": [] }, "phat_InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InvestorsFundingCommitmentPotentialAmountAvailableUponAchievementOfSalesMilestone", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors funding commitment potential amount available upon achievement of sales milestone", "label": "Investors Funding Commitment Potential Amount Available Upon Achievement of Sales Milestone", "documentation": "Investors funding commitment potential amount available upon achievement of sales milestone." } } }, "auth_ref": [] }, "phat_InvestorsReceiptDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InvestorsReceiptDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors receipt description", "label": "Investors Receipt Description", "documentation": "Investors receipt description." } } }, "auth_ref": [] }, "phat_InvestorsRightToReceiveRoyaltiesTerminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "InvestorsRightToReceiveRoyaltiesTerminationDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investors right to receive royalties termination description", "label": "Investors Right to Receive Royalties Termination Description", "documentation": "Investors right to receive royalties termination description." } } }, "auth_ref": [] }, "phat_JoinderAgreementAdditionalFundingUponFdaApprovalOrDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "JoinderAgreementAdditionalFundingUponFdaApprovalOrDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Joinder agreement additional funding upon fda approval or during the fourth quarter of two thousand twenty and three.", "label": "Joinder Agreement Additional Funding Upon Fda Approval Or During the Fourth Quarter Of Two Thousand Twenty And Three [Member]", "terseLabel": "Joinder Agreement Additional Funding Upon FDA Approval or During the Fourth Quarter of 2023" } } }, "auth_ref": [] }, "phat_JoinderAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "JoinderAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Joinder Agreement.", "label": "Joinder Agreement [Member]", "terseLabel": "Joinder Agreement" } } }, "auth_ref": [] }, "phat_LanderWarrantsExpireTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LanderWarrantsExpireTerm", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lander warrants expire term.", "label": "Lander Warrants Expire Term", "terseLabel": "Warrants expire term" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "phat_LenderWarrantsExercisableSharesOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LenderWarrantsExercisableSharesOfCommonStock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lender warrants exercisable shares of common stock.", "label": "Lender Warrants Exercisable Shares Of Common Stock", "terseLabel": "Warrants exercisable shares of common stock" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r548", "r556", "r1209" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r548", "r556", "r1209" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Summary of Future Minimum Lease Payments Under Operating Leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1212" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r554", "r1083", "r1087", "r1229" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1212" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r554" ] }, "phat_LesseeOperatingLeaseNumberOfOptionToExtend": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LesseeOperatingLeaseNumberOfOptionToExtend", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease number of option to extend.", "label": "Lessee Operating Lease Number Of Option To Extend", "terseLabel": "Operating lease number of option to extend" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Operating lease, option to extend description", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r549" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating leases, remaining lease terms", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r556", "r1210" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease, renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1211" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitments" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Lease Commitments", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r543" ] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessor, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r52", "r54", "r55", "r557" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r68", "r69", "r131", "r134", "r135", "r223", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r478", "r481", "r482", "r531", "r715", "r814", "r841", "r903", "r1020", "r1140", "r1215", "r1216" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r104", "r619", "r620", "r630", "r649", "r873", "r890", "r891", "r1082", "r1086", "r1118", "r1203" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r68", "r69", "r72", "r87", "r131", "r134", "r135", "r223", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r478", "r481", "r482", "r531", "r873", "r1140", "r1215", "r1216" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "phat_LicenseAgreementDescription": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LicenseAgreementDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement description.", "label": "License Agreement Description", "terseLabel": "License agreement description" } } }, "auth_ref": [] }, "phat_LiquidityAndCapitalResourcesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LiquidityAndCapitalResourcesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Liquidity and capital resources.", "label": "Liquidity And Capital Resources Policy [Text Block]", "terseLabel": "Liquidity and Capital Resources" } } }, "auth_ref": [] }, "phat_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LoanAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Loan agreement.", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "totalLabel": "Total debt, net of debt discount", "terseLabel": "Total principal payments", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r132", "r141", "r312", "r327", "r619", "r620", "r624", "r638", "r837", "r838", "r871", "r1002", "r1011", "r1230" ] }, "phat_LongTermDebtAndInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtAndInterest", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt and interest.", "label": "Long Term Debt And Interest", "totalLabel": "Total principal payments" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "verboseLabel": "Long-term debt, current portion", "totalLabel": "Long-term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r797", "r799" ] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal and interest, year one.", "label": "Long Term Debt Maturities Repayments Of Principal And Interest Due Next Twelve Months", "terseLabel": "2026" } } }, "auth_ref": [] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Four", "documentation": "Long term debt maturities repayments of principal and interest in year four.", "terseLabel": "2029" } } }, "auth_ref": [] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal and interest in year three.", "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Three", "terseLabel": "2028" } } }, "auth_ref": [] }, "phat_LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails": { "parentTag": "phat_LongTermDebtAndInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfFutureMinimumPrincipalAndInterestPaymentsUnderTermLoansDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt maturities repayments of principal and interest in year two.", "label": "Long Term Debt Maturities Repayments Of Principal And Interest In Year Two", "terseLabel": "2027" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of discount", "totalLabel": "Long-term Debt, Excluding Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r1002", "r1011" ] }, "phat_LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "LongTermDebtNoncurrentExcludingUnamortizedDebtDiscount", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtScheduleOfTotalDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Long term debt noncurrent excluding unamortized debt discount.", "label": "Long Term Debt Noncurrent Excluding Unamortized Debt Discount", "terseLabel": "Long-term debt, non-current portion" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r79", "r88", "r89", "r90", "r91", "r92", "r619", "r620", "r624", "r1128", "r1129", "r1130" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r11", "r79", "r88", "r89", "r90", "r91", "r92", "r619", "r620", "r624", "r1128", "r1129", "r1130" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MajorCustomersAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r221", "r842", "r845", "r883", "r888", "r1232", "r1234", "r1235", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "us-gaap_MarketingAndAdvertisingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MarketingAndAdvertisingExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Marketing and Advertising Expense, Total", "label": "Marketing and Advertising Expense", "terseLabel": "Advertising and marketing costs", "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising." } } }, "auth_ref": [ "r23", "r808" ] }, "phat_MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MaximumAmountPayableInSalesMilestonesUponAchievementOfSpecifiedLevelsOfProductSales", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum amount payable in sales milestones upon the achievement of specified levels of product sales.", "label": "Maximum Amount Payable In Sales Milestones Upon Achievement Of Specified Levels Of Product Sales", "terseLabel": "Maximum amount payable in sales milestones upon achievement of specified levels of product sales" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": [ "r70", "r71", "r178", "r284", "r285", "r286", "r287", "r393", "r423", "r424", "r425", "r439", "r521", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r582", "r675", "r677", "r691", "r707", "r708", "r758", "r760", "r762", "r763", "r765", "r769", "r770", "r772", "r773", "r786", "r787", "r830", "r850", "r854", "r856", "r857", "r865", "r866", "r867", "r868", "r884", "r1142", "r1144" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r952" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r952" ] }, "phat_MinimumCashBalanceConditionOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashBalanceConditionOneMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Balance Condition One [Member]", "documentation": "Minimum Cash Balance Condition One [Member]", "terseLabel": "Minimum Cash Balance Condition One" } } }, "auth_ref": [] }, "phat_MinimumCashBalanceConditionTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashBalanceConditionTwoMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Balance Condition Two [Member]", "documentation": "Minimum cash balance condition two.", "terseLabel": "Minimum Cash Balance Condition Two" } } }, "auth_ref": [] }, "phat_MinimumCashRequirement100PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashRequirement100PercentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Requirement 100 Percent [Member]", "documentation": "Minimum cash requirement 100 percent.", "terseLabel": "Minimum Cash Requirement (100%)" } } }, "auth_ref": [] }, "phat_MinimumCashRequirement30MillionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashRequirement30MillionMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum Cash Requirement", "label": "Minimum Cash Requirement 30 Million [Member]", "documentation": "Minimum cash requirement 30 million." } } }, "auth_ref": [] }, "phat_MinimumCashRequirement50PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashRequirement50PercentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Requirement 50 Percent [Member]", "documentation": "Minimum cash requirement 50 percent.", "terseLabel": "Minimum Cash Requirement (50%)" } } }, "auth_ref": [] }, "phat_MinimumCashRequirement75PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumCashRequirement75PercentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum Cash Requirement 75 Percent [Member]", "documentation": "Minimum cash requirement 75 percent.", "terseLabel": "Minimum Cash Requirement (75%)" } } }, "auth_ref": [] }, "phat_MinimumMarketCapitalizationAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumMarketCapitalizationAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum market capitalization amount.", "label": "Minimum Market Capitalization Amount", "terseLabel": "Minimum market capitalization amount" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r70", "r71", "r178", "r284", "r285", "r286", "r287", "r393", "r423", "r424", "r425", "r439", "r521", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r582", "r675", "r677", "r691", "r707", "r708", "r758", "r760", "r762", "r763", "r765", "r769", "r770", "r772", "r773", "r786", "r787", "r830", "r850", "r854", "r856", "r857", "r865", "r866", "r867", "r884", "r1142", "r1144" ] }, "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountFollowingThirdPerformanceMilestone", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of qualified cash on principal amount following third performance milestone.", "label": "Minimum Percentage of Qualified Cash on Principal Amount Following Third Performance Milestone", "terseLabel": "Minimum percentage of qualified cash following third performance milestone" } } }, "auth_ref": [] }, "phat_MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumPercentageOfQualifiedCashOnPrincipalAmountPriorToThirdPerformanceMilestone", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum percentage of qualified cash on principal amount prior to third performance milestone.", "label": "Minimum Percentage of Qualified Cash on Principal Amount Prior to Third Performance Milestone", "terseLabel": "Percentage of qualified cash prior to Third performance milestone" } } }, "auth_ref": [] }, "phat_MinimumProjectionPercentageOnSaleOfVonoprazanAndProductsContainingVonoprazan": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "MinimumProjectionPercentageOnSaleOfVonoprazanAndProductsContainingVonoprazan", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum projection percentage on sale of vonoprazan and products containing vonoprazan", "label": "Minimum Projection Percentage on Sale of Vonoprazan and Products Containing Vonoprazan", "documentation": "Minimum projection percentage on sale of vonoprazan and products containing vonoprazan." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r971" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r979" ] }, "stpr_NJ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2026", "localname": "NJ", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "NEW JERSEY", "terseLabel": "Florham Park, New Jersey" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "auth_ref": [ "r221", "r842", "r845", "r883", "r888", "r1232", "r1234", "r1235", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r953" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r123" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r123" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r30", "r31", "r32" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r21", "r32", "r43", "r63", "r68", "r69", "r108", "r109", "r113", "r131", "r134", "r135", "r138", "r146", "r151", "r152", "r153", "r154", "r155", "r158", "r159", "r164", "r223", "r254", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r333", "r336", "r338", "r342", "r357", "r384", "r435", "r463", "r474", "r517", "r531", "r654", "r736", "r752", "r753", "r806", "r808", "r809", "r901", "r1140" ] }, "phat_NetProceedsAfterDeductingUnderwritersCommission": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NetProceedsAfterDeductingUnderwritersCommission", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds after deducting underwriters commission.", "label": "Net Proceeds After Deducting Underwriters Commission", "terseLabel": "Net proceeds after deducting underwriters commission" } } }, "auth_ref": [] }, "phat_NetProceedsFromIssuanceOfAtTheMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NetProceedsFromIssuanceOfAtTheMarketOffering", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds from issuance of at the market offering.", "label": "Net Proceeds From Issuance of at the Market Offering", "terseLabel": "Net Proceeds from At the Market Offering (ATM)" } } }, "auth_ref": [] }, "phat_NetProceedsFromIssuanceOfInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NetProceedsFromIssuanceOfInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Net proceeds from issuance of initial public offering.", "label": "Net Proceeds From Issuance of Initial Public Offering", "terseLabel": "Net Proceeds from Initial Public Offering (IPO)" } } }, "auth_ref": [] }, "phat_NetProceedsFromRevenueInterestFinancingTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NetProceedsFromRevenueInterestFinancingTransaction", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "label": "Net Proceeds From Revenue Interest Financing Transaction", "documentation": "Net proceeds from revenue interest financing transaction.", "verboseLabel": "Net proceeds from revenue interest financing transaction" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ "r160" ] }, "phat_NonCashFinalInterestPaymentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NonCashFinalInterestPaymentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Non cash final interest payment fee.", "label": "Non Cash Final Interest Payment Fee", "terseLabel": "Final interest payment fee" } } }, "auth_ref": [] }, "phat_NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NonCashSettlementOfDefinedContributionPlanLiabilityInCommonStock", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "NonCash settlement of defined contribution plan liability in common stock.", "label": "Non Cash Settlement Of Defined Contribution Plan Liability In Common Stock", "terseLabel": "Settlement of 401(k) liability in common stock" } } }, "auth_ref": [] }, "phat_NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NonCashSettlementOfEmployeeStockPurchasePlanLiabilityInCommonStock", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "documentation": "NonCash settlement of employee stock purchase plan liability in common stock.", "label": "Non Cash Settlement Of Employee Stock Purchase Plan Liability In Common Stock", "terseLabel": "Settlement of ESPP liability in common stock" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r952" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r916", "r926", "r936", "r960", "r968" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r943" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r942" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r960" ] }, "phat_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arr Modified Flag", "documentation": "Non-rule 10b5-1 Arr modified flag.", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r979" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r979" ] }, "phat_NonfinancialAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NonfinancialAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Nonfinancial assets fair value disclosure.", "label": "Nonfinancial Assets Fair Value Disclosure", "terseLabel": "Non-financial assets fair value disclosure" } } }, "auth_ref": [] }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonfinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Nonfinancial Liabilities Fair Value Disclosure", "terseLabel": "Non-financial liabilities fair value disclosure", "totalLabel": "Nonfinancial Liabilities Fair Value Disclosure, Total", "documentation": "Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities." } } }, "auth_ref": [ "r1194", "r1195", "r1201" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r24", "r995", "r996", "r1118" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income:", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "phat_NumberOfCustomersAccountedForAccountsReceivable": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NumberOfCustomersAccountedForAccountsReceivable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of customers accounted for accounts receivable..", "label": "Number Of Customers Accounted For Accounts Receivable", "terseLabel": "Number of customers accounted for accounts receivable" } } }, "auth_ref": [] }, "phat_NumberOfCustomersAccountedForProductSales": { "xbrltype": "integerItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "NumberOfCustomersAccountedForProductSales", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of customers accounted for product sales.", "label": "Number Of Customers Accounted For Product Sales", "terseLabel": "Number of customers accounted for product sales" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r823", "r1101" ] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segment", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r816", "r828", "r1101" ] }, "phat_OfficersOrDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OfficersOrDirectorsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Officers or Directors [Member]", "documentation": "Officers or Directors." } } }, "auth_ref": [] }, "phat_OpenMarketSaleAgreementWithJefferiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OpenMarketSaleAgreementWithJefferiesLLCMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Open Market Sale Agreement with Jefferies LLC.", "label": "Open Market Sale Agreement With Jefferies L L C [Member]", "terseLabel": "Open Market Sale Agreement with Jefferies LLC" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [ "r809", "r995", "r996", "r1118" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r806", "r809", "r815", "r995", "r996", "r1094", "r1102", "r1108", "r1111", "r1112", "r1118" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating leases, rent expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1208" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities", "totalLabel": "Present value of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r546" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: operating lease liabilities, current", "terseLabel": "Operating lease liabilities, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r546", "r796" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails2": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, non-current", "verboseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r546" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Cash payments for operating lease costs", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r547", "r551" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r545" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average incremental borrowing rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r553", "r872" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsSummaryOfFutureAnnualMinimumLeasePaymentsUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r552", "r872" ] }, "phat_OrganizationAndBasisOfPresentationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OrganizationAndBasisOfPresentationPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Organization and basis of presentation.", "label": "Organization and Basis of Presentation [Policy Text Block]", "terseLabel": "Organization and Basis of Presentation" } } }, "auth_ref": [] }, "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization basis of presentation and summary of significant accounting policies.", "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "phat_OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Organization basis of presentation and summary of significant accounting policies.", "label": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]", "terseLabel": "Organization Basis Of Presentation And Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Organization, Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r42", "r994", "r1081" ] }, "phat_OrganizationPolicyTextBlcok": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OrganizationPolicyTextBlcok", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Organization [Policy Text Blcok]", "documentation": "Organization [Policy Text Blcok]", "terseLabel": "Organization" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1006" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r77", "r81" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r78", "r83", "r86", "r873" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r96", "r1012" ] }, "phat_OtherLongTermAssetsPolicyTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "OtherLongTermAssetsPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Other Long-Term Assets.", "label": "Other Long-Term Assets [Policy Text Block]", "terseLabel": "Other Long-Term Assets" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r32" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "terseLabel": "Other (expense) income, net", "verboseLabel": "Other expense, net", "negatedLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r26", "r860" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r952" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r914", "r924", "r934", "r966" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r917", "r927", "r937", "r969" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r917", "r927", "r937", "r969" ] }, "us-gaap_OverAllotmentOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OverAllotmentOptionMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Over-Allotment Option [Member]", "terseLabel": "Underwritten Public Offering", "documentation": "Right given to the underwriter to sell additional shares over the initial allotment." } } }, "auth_ref": [] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PartnerTypeOfPartnersCapitalAccountAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type [Axis]", "terseLabel": "Partner Type", "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r355", "r359", "r702" ] }, "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Partner Type of Partners' Capital Account, Name [Domain]", "terseLabel": "Partner Type of Partners' Capital Account, Name", "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests." } } }, "auth_ref": [ "r355", "r359", "r702" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r941" ] }, "phat_PaymentForFacilityCharge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PaymentForFacilityCharge", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for facility charge.", "label": "Payment for Facility Charge", "terseLabel": "Payment for facility charge" } } }, "auth_ref": [] }, "phat_PaymentForLicenseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PaymentForLicenseAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment for license amount.", "label": "Payment For License Amount", "terseLabel": "Cash consideration paid for license" } } }, "auth_ref": [] }, "phat_PaymentInKindPikInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PaymentInKindPikInterestRateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payment in kind PIK interest rate.", "label": "Payment in Kind PIK Interest Rate [Member]", "terseLabel": "Payment In Kind PIK Interest Rate" } } }, "auth_ref": [] }, "phat_PaymentOfEmployeeTaxObligationsRelatedToVestingOfPerformanceStockUnitsAndRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PaymentOfEmployeeTaxObligationsRelatedToVestingOfPerformanceStockUnitsAndRestrictedStockUnits", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of employee tax obligations related to vesting of PSUs and RSUs", "label": "Payment Of Employee Tax Obligations Related To Vesting Of Performance Stock Units And Restricted Stock Units", "documentation": "Payment of employee tax obligations related to vesting of performance stock units and restricted stock units." } } }, "auth_ref": [] }, "phat_PaymentOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PaymentOfTransactionCosts", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: transaction costs", "terseLabel": "Transaction costs", "label": "Payment of Transaction Costs", "documentation": "Payment of transaction costs." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Warrants", "terseLabel": "Aggregate repurchase price of warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Restructuring", "negatedLabel": "Cash paid", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r273", "r1077" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issuance costs", "label": "Payments of Stock Issuance Costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash paid for property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r27" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r951" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r951" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r943" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r960" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r953" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r942" ] }, "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestorOnNetSales", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate payments on investment amount to investors on net sales", "label": "Percentage Of Aggregate Payments On Investment Amount To Investors On Net Sales", "documentation": "Percentage of aggregate payments on investment amount to investors on net sales." } } }, "auth_ref": [] }, "phat_PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfAggregatePaymentsOnInvestmentAmountToInvestors", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of aggregate payment on investment amount to investors", "label": "Percentage Of Aggregate Payments On Investment Amount To Investors", "documentation": "Percentage of aggregate payments on investment amount to investors." } } }, "auth_ref": [] }, "phat_PercentageOfCashInterestUponAchievingMilestone": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfCashInterestUponAchievingMilestone", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of cash interest upon achieving milestone.", "label": "Percentage of cash interest upon achieving milestone", "terseLabel": "Percentage of cash interest upon achieving milestone" } } }, "auth_ref": [] }, "phat_PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfDebtFundedToBeIssuedAsWarrantsToPurchaseCommonStock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of debt funded to be issued as warrants to purchase common stock.", "label": "Percentage of Debt Funded to be Issued as Warrants to Purchase Common Stock", "terseLabel": "Percentage of debt funded to be issued as warrants to purchase common stock" } } }, "auth_ref": [] }, "phat_PercentageOfGrossSalesPricePerShareSold": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfGrossSalesPricePerShareSold", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of gross sales price per share sold.", "label": "Percentage Of Gross Sales Price Per Share Sold", "terseLabel": "Percentage of gross sales price per share sold" } } }, "auth_ref": [] }, "phat_PercentageOfInvestorShareOfRoyaltyInNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfInvestorShareOfRoyaltyInNetSales", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of investor share of royalty in net sales", "documentation": "Percentage of investor share of royalty in net sales.", "label": "Percentage of investor share of royalty in net sales" } } }, "auth_ref": [] }, "phat_PercentageOfModificationOfTheExistingDebtOrAnExtinguishmentOfTheOldDebtAndIssuanceOfNewDebt": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfModificationOfTheExistingDebtOrAnExtinguishmentOfTheOldDebtAndIssuanceOfNewDebt", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of Modification of the Existing Debt or an Extinguishment of the Old Debt and Issuance of New Debt", "documentation": "Percentage of modification of the existing debt or an extinguishment of the old debt and issuance of new debt.", "terseLabel": "Percentage of modification of the existing debt or an extinguishment of the old debt and issuance of new debt" } } }, "auth_ref": [] }, "phat_PercentageOfTotalRevenueRepresentedByProduct": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PercentageOfTotalRevenueRepresentedByProduct", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage Of Total Revenue Represented By Product", "documentation": "Percentage of total revenue represented by product.", "terseLabel": "Percentage of total revenue represented by product" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PerformanceSharesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Performance Shares [Member]", "terseLabel": "Performance-Based Stock Units (PSU)", "verboseLabel": "Performance Shares", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r944" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r988" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r943" ] }, "phat_PotentialAdditionalInvestorFundingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PotentialAdditionalInvestorFundingAmount", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potential additional investor funding amount", "label": "Potential Additional Investor Funding Amount", "documentation": "Potential additional investor funding amount." } } }, "auth_ref": [] }, "phat_PreFundedWarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PreFundedWarrantsPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrants.", "label": "Pre-Funded Warrants Policy [Policy Text Block]", "terseLabel": "Pre-funded Warrants" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r344", "r998", "r1013", "r1147", "r1223", "r1224", "r1227" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized shares", "verboseLabel": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r74", "r100", "r352", "r619", "r620", "r627", "r717" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued shares", "verboseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r74", "r100", "r344", "r352", "r619", "r620", "r627" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, outstanding shares", "verboseLabel": "Preferred stock, shares outstanding", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r74", "r100", "r352", "r619", "r620", "r627", "r717", "r735", "r1145", "r1276", "r1277" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.0001 par value; authorized shares -40,000,000 at June 30, 2026 and December 31, 2025; no shares issued and outstanding at June 30, 2026 and December 31, 2025", "label": "Preferred Stock, Value, Issued", "totalLabel": "Preferred Stock, Value, Issued, Total", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r74", "r100", "r335", "r340", "r352", "r619", "r620", "r627", "r646", "r873" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1019" ] }, "phat_PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Prepaid expenses and other assets related parties current.", "label": "Prepaid Expenses And Other Assets Related Parties Current", "terseLabel": "Prepaid expenses and other current assets, related parties" } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrimeRateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "terseLabel": "Prime Rate", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [ "r1002", "r1007", "r1139" ] }, "phat_PriorToThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PriorToThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Prior to Three Months Trailing.", "label": "Prior to Three Months Trailing [Member]", "terseLabel": "Prior to Three Months Trailing" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "verboseLabel": "Proceeds from Initial Public Offering (IPO)", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r1" ] }, "phat_ProceedsFromIssuanceInitialPublicOfferingGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ProceedsFromIssuanceInitialPublicOfferingGross", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance initial public offering gross.", "label": "Proceeds From Issuance Initial Public Offering Gross", "terseLabel": "Proceeds from issuance initial public offering gross" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of shares", "verboseLabel": "Net proceeds from issuance of common stock", "label": "Net proceeds from issuance of common stock under ATM facility", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "phat_ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantGross": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantGross", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock and pre-funded warrant gross", "documentation": "Proceeds from issuance of common stock and pre-funded warrant gross.", "label": "Proceeds from Issuance of Common Stock and Pre-funded Warrant Gross" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of long-term debt, net of issuance costs", "label": "Proceeds from Issuance of Long-Term Debt", "totalLabel": "Proceeds from Issuance of Long-Term Debt, Total", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r8", "r696" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from issuance of pre-funded warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r1" ] }, "phat_ProceedsFromIssuanceUnderwrittenPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ProceedsFromIssuanceUnderwrittenPublicOffering", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds From Issuance Underwritten Public Offering", "documentation": "Proceeds from issuance underwritten public offering.", "terseLabel": "Net proceeds from underwritten public offering" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromLongTermLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Long-Term Lines of Credit", "terseLabel": "Proceeds from remaining line of credit", "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r1", "r7" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r217", "r584", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r789", "r805", "r808", "r809", "r842", "r843", "r882", "r884", "r885", "r889", "r892", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1137", "r1138", "r1232", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r217", "r584", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r789", "r805", "r808", "r809", "r842", "r843", "r882", "r884", "r885", "r889", "r892", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1073", "r1074", "r1075", "r1076", "r1137", "r1138", "r1232", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1265", "r1266", "r1267", "r1268", "r1269", "r1270", "r1271", "r1272" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "verboseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r63", "r68", "r69", "r108", "r109", "r125", "r131", "r134", "r135", "r138", "r146", "r155", "r158", "r159", "r223", "r254", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r333", "r357", "r384", "r435", "r463", "r474", "r476", "r479", "r480", "r517", "r531", "r634", "r636", "r653", "r699", "r736", "r752", "r753", "r791", "r858", "r859", "r902", "r1030", "r1140" ] }, "phat_ProjectedRevenueInTwoThousandTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ProjectedRevenueInTwoThousandTwentySevenMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Projected Revenue in Two Thousand Twenty Seven [Member]", "documentation": "Projected revenue in two thousand twenty seven,", "terseLabel": "Projected Revenue in 2027" } } }, "auth_ref": [] }, "phat_ProjectedRevenuesInTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ProjectedRevenuesInTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Projected Revenues In Two Thousand Twenty Six [Member]", "documentation": "Projected revenues in two thousand twenty six.", "terseLabel": "Projected Revenue in 2026" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Class [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r257", "r258", "r555", "r832", "r833", "r834", "r835", "r1120", "r1121", "r1220" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r555", "r619", "r620", "r632", "r639", "r640", "r652", "r873", "r1124" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net", "label": "Property, Plant, and Equipment [Policy Text Block]", "documentation": "Disclosure of accounting policy for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r51", "r56", "r259", "r260", "r651", "r1120" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Long-Lived Asset, Class [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r257", "r258", "r555", "r832", "r833", "r834", "r835", "r1120", "r1121", "r1220" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, Useful Life", "terseLabel": "Property and equipment, useful life", "documentation": "Useful life of property, plant, and equipment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r1122" ] }, "phat_PurchaseCommitmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PurchaseCommitmentExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase commitment, expense.", "label": "Purchase Commitment Expense", "terseLabel": "Expenses incurred related to purchase commitments" } } }, "auth_ref": [] }, "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Remaining Minimum Amount Committed", "terseLabel": "Minimum purchase obligation", "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations." } } }, "auth_ref": [ "r1135" ] }, "phat_PurchaseObligationDueInFirstTwentyFourMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PurchaseObligationDueInFirstTwentyFourMonths", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase obligation due in first twenty four months.", "label": "Purchase Obligation Due In First Twenty Four Months", "terseLabel": "Purchase obligation in the first 24-month period" } } }, "auth_ref": [] }, "phat_PurchaseOfAdditionalOfferingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "PurchaseOfAdditionalOfferingExpenses", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of additional offering expenses.", "label": "Purchase Of Additional Offering Expenses", "terseLabel": "Purchase of additional offering expenses" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r941" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r941" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r70", "r71", "r178", "r284", "r285", "r286", "r287", "r389", "r393", "r423", "r424", "r425", "r432", "r439", "r521", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r675", "r677", "r691", "r707", "r708", "r758", "r760", "r762", "r763", "r765", "r769", "r770", "r772", "r773", "r786", "r787", "r830", "r850", "r854", "r856", "r857", "r865", "r866", "r867", "r868", "r884", "r895", "r1131", "r1142", "r1144", "r1197" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r70", "r71", "r178", "r284", "r285", "r286", "r287", "r389", "r393", "r423", "r424", "r425", "r432", "r439", "r521", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r582", "r675", "r677", "r691", "r707", "r708", "r758", "r760", "r762", "r763", "r765", "r769", "r770", "r772", "r773", "r786", "r787", "r830", "r850", "r854", "r856", "r857", "r865", "r866", "r867", "r868", "r884", "r895", "r1131", "r1142", "r1144", "r1197" ] }, "phat_RebatesReturnsAndCo-PayAssistanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RebatesReturnsAndCo-PayAssistanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Rebates, Returns and Co-Pay Assistance [Member]", "documentation": "Rebates, returns and co-pay assistance.", "terseLabel": "Rebates, Returns and Co-Pay Assistance" } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Receivables, Net, Current, Total", "label": "Receivables, Net, Current", "terseLabel": "Accounts receivable, net", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r873" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r909", "r919", "r929", "r961" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r78", "r79", "r83", "r93", "r95", "r131", "r137", "r138", "r222", "r390", "r391", "r564", "r565", "r619", "r620", "r622", "r623", "r624", "r631", "r644", "r650", "r710", "r711", "r712", "r713", "r714", "r734", "r757", "r794", "r1274", "r1278" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "terseLabel": "Related Party", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r78", "r79", "r83", "r93", "r95", "r131", "r137", "r138", "r564", "r565", "r566", "r567", "r619", "r620", "r624", "r644", "r650", "r710", "r711", "r712", "r713", "r714", "r734", "r757" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r78", "r79", "r83", "r93", "r95", "r131", "r137", "r138", "r222", "r390", "r391", "r564", "r565", "r619", "r620", "r622", "r623", "r624", "r631", "r644", "r650", "r710", "r711", "r712", "r713", "r714", "r734", "r757", "r794", "r1214", "r1274", "r1278" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total", "negatedLabel": "Repayment of long-term debt", "terseLabel": "Repayment of long-term debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r697" ] }, "us-gaap_ReportableSegmentAggregationBeforeOtherOperatingSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ReportableSegmentAggregationBeforeOtherOperatingSegmentMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Reportable Segment, Aggregation before Other Operating Segment [Member]", "terseLabel": "Reportable Segment, Aggregation before Other Operating Segment", "documentation": "Aggregation of reportable segments before other operating segment. Excludes intersegment elimination and reconciling item." } } }, "auth_ref": [ "r822", "r823" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r131", "r139", "r140", "r303", "r345", "r567", "r570", "r580", "r642", "r801", "r802", "r803", "r1021", "r1022", "r1023", "r1024", "r1025", "r1026", "r1027", "r1028", "r1029", "r1188", "r1189", "r1190", "r1191", "r1218", "r1219" ] }, "phat_RepurchaseRightLapseRate": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RepurchaseRightLapseRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Repurchase right lapse rate.", "label": "Repurchase Right Lapse Rate", "terseLabel": "Initial repurchase right lapse rate" } } }, "auth_ref": [] }, "phat_RepurchaseRightLapseShares": { "xbrltype": "decimalItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RepurchaseRightLapseShares", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Repurchase right lapse shares.", "label": "Repurchase Right Lapse Shares", "terseLabel": "Repurchase right lapse each month after first anniversary, shares" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "totalLabel": "Research and Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r441", "r788", "r806", "r807", "r822", "r1221" ] }, "phat_ResearchAndDevelopmentExpenseExcludingStockBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ResearchAndDevelopmentExpenseExcludingStockBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Research and development expense excluding stock based compensation expense", "documentation": "Research and development expense excluding stock-based compensation expense.", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Expenses and Accruals", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r440" ] }, "phat_ResearchAndDevelopmentExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ResearchAndDevelopmentExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Research and development expense related party.", "label": "Research And Development Expense Related Party", "terseLabel": "Research and development expenses, related party" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r910", "r920", "r930", "r962" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r911", "r921", "r931", "r963" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r918", "r928", "r938", "r970" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r126", "r130", "r1003", "r1222", "r1223", "r1224", "r1225", "r1231" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r1093", "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuring1" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": [ "r270", "r271", "r273", "r276", "r281" ] }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringAndRelatedCostIncurredCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Restructuring expenses incurred", "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost." } } }, "auth_ref": [ "r272", "r275", "r277", "r280" ] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated", "terseLabel": "Reduction in number of employees on restructuring", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of reduction in number of employees on restructuring", "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } }, "auth_ref": [] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringChargesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringCostAndReserveAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r116", "r117", "r272", "r273", "r277", "r278", "r807" ] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringCostAndReserveLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringCosts", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Costs", "totalLabel": "Restructuring Costs, Total", "terseLabel": "Restructuring charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r3" ] }, "phat_RestructuringNon-CashExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RestructuringNon-CashExpenses", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Non-cash expenses", "label": "Restructuring Non-cash Expenses", "documentation": "Restructuring non-cash expenses." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringSummaryOfActivityRelatedToRestructuringAccrualDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Restructuring accrual as of June 30", "periodStartLabel": "Restructuring accrual as of January 1", "label": "Restructuring Reserve", "totalLabel": "Restructuring Reserve, Total", "terseLabel": "Restructuring related accruals", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r273", "r278" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r103", "r354", "r619", "r620", "r629", "r648", "r685", "r690", "r698", "r718", "r873" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r62", "r63", "r142", "r143", "r144", "r147", "r155", "r157", "r159", "r224", "r227", "r253", "r254", "r256", "r332", "r351", "r360", "r382", "r383", "r387", "r388", "r435", "r452", "r453", "r459", "r460", "r461", "r464", "r473", "r474", "r490", "r491", "r492", "r493", "r495", "r496", "r499", "r515", "r544", "r581", "r641", "r681", "r683", "r700", "r1150", "r1151", "r1276" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "phat_RevenueFromContractWithCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueFromContractWithCustomerLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Line Items]", "documentation": "Revenue from contract with customer." } } }, "auth_ref": [] }, "phat_RevenueFromContractWithCustomerTable": { "xbrltype": "stringItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueFromContractWithCustomerTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionSummaryOfRevenueAllowancesAndRelatedAccrualsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Table]", "documentation": "Revenue from contract with customer." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r57", "r367", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r377", "r379" ] }, "phat_RevenueInterestFinancingAgreementFundingCommitmentOnDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementFundingCommitmentOnDuringTheFourthQuarterOfTwoThousandTwentyAndThreeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing agreement funding commitment on during the fourth quarter of two thousand twenty and three.", "label": "Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter Of Two Thousand Twenty And Three [Member]", "terseLabel": "Revenue Interest Financing Agreement Funding Commitment On During the Fourth Quarter of 2023" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementFundingCommitmentOnOrBeforeMarchThirtyOneTwoThousandAndTwentyFourMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement, Funding Commitment On or Before March 31, 2024", "label": "Revenue Interest Financing Agreement Funding Commitment On Or Before March Thirty One Two Thousand And Twenty Four [Member]", "documentation": "Revenue interest financing agreement funding commitment on or before March thirty one two thousand and twenty four." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementFundingUponAchievementOfSalesMilestoneAtAnyTimePriorToJuneThirtyTwoThousandAndTwentyFourMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Funding upon Achievement of Sales Milestone at any Time Prior to June 30, 2024", "label": "Revenue Interest Financing Agreement Funding Upon Achievement of Sales Milestone At Any Time prior To June Thirty Two Thousand and Twenty Four [Member]", "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon achievement of sales milestone at any time prior to June thirty two thousand and twenty four." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementFundingUponFdaApprovalAtAnyTimePriorToDecemberThirtyOneTwoThousandAndTwentyTwoMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Funding upon FDA Approval at any Time Prior to December 31, 2022", "label": "Revenue Interest Financing Agreement Funding Upon FDA Approval At Any Time prior To December Thirty One Two Thousand and Twenty Two [Member]", "documentation": "Revenue \u200binterest\u200b financing\u200b agreement\u200b funding upon FDA approval at any time prior to December thirty one two thousand and twenty two." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue Interest Financing Agreement [Member]", "label": "Revenue Interest Financing Agreement" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndThirtySevenMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Percentage On Investment Amount by December 31, 2037", "label": "Revenue Interest Financing Agreement Percentage On Investment Amount On December Thirty One Two Thousand And Thirty Seven [Member]", "documentation": "Revenue interest financing agreement percentage on investment amount On December thirty one two thousand and thirty seven." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementPercentageOnInvestmentAmountOnDecemberThirtyOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Percentage on Investment Amount On December December 31, 2028", "label": "Revenue Interest Financing Agreement Percentage on Investment Amount On December Thirty One Two Thousand And Twenty Eight [Member]", "documentation": "Revenue interest financing agreement percentage on investment amount on December thirty one two thousand and twenty eight." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrenceIsThereafterToMayThreeTwoThousandAndTwentyThreeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA approval If occurrence is Thereafter to May 3, 2023", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA approval If occurrence is Thereafter to May Three Two Thousand and Twenty Three [Member]", "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is thereafter to May three two thousand and twenty three." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalIfOccurrencePriorToMayThreeTwoThousandAndTwentyThreeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval If Occurrence Prior to May Three Two Thousand and Twenty Three [Member]", "documentation": "Revenue interest financing agreement upon occurrence of a change in control event earlier of April one two thousand and twenty four or FDA approval If occurrence is prior to May three two thousand and twenty three." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfAChangeInControlEventEarlierOfAprilOneTwoThousandAndTwentyFourOrFdaApprovalMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April 1, 2024 or FDA Approval If Occurrence Prior May 3, 2023", "label": "Revenue Interest Financing Agreement Upon Occurrence of a Change in Control Event Earlier of April One Two Thousand and Twenty Four or FDA Approval [Member]", "documentation": "Revenue interest financing agreement upon occurrence of a Change in control event earlier of April one two thousand and twenty four or FDA Approval." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultAfterAprilOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default after April 1, 2028", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default After April One Two Thousand and Twenty Eight [Member]", "documentation": "Revenue interest financing agreement upon occurrence of event of default after April one two thousand and twenty eight." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultBetweenAprilOneTwoThousandAndTwentyFiveAndAprilOneTwoThousandAndTwentyEightMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default between April 1, 2025, and April 1, 2028", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Between April One Two Thousand and Twenty Five and April One Two Thousand and Twenty Eight [Member]", "documentation": "Revenue interest financing agreement upon occurrence of event between April one two thousand and twenty five and April one two thousand and twenty eight." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingAgreementUponOccurrenceOfEventOfDefaultPriorToAprilOneTwoThousandAndTwentyFiveMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default Prior to April 1, 2025", "label": "Revenue Interest Financing Agreement Upon Occurrence of Event of Default prior to April One Two thousand and Twenty Five [Member]", "documentation": "Revenue interest financing agreement upon occurrence of event of default prior to April one two thousand and twenty five." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingLiability", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending liability balance", "terseLabel": "Revenue interest financing liability", "label": "Revenue Interest Financing Liability", "documentation": "Revenue interest financing liability.", "periodStartLabel": "Beginning liability balance" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingLiabilityEffectiveInterestRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue interest financing liability, effective interest rate", "label": "Revenue interest financing liability effective interest rate", "documentation": "Revenue interest financing liability effective interest rate." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest financing liability noncurrent.", "label": "Revenue Interest Financing Liability Noncurrent", "negatedLabel": "Less: current portion", "terseLabel": "Long-term liability ending balance", "periodEndLabel": "Long-term liability ending balance" } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingLiabilityPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Liability", "label": "Revenue Interest Financing Liability [Policy Text Block]", "documentation": "Revenue interest financing liability." } } }, "auth_ref": [] }, "phat_RevenueInterestFinancingLiabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestFinancingLiabilityTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiability" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Interest Financing Liability", "label": "Revenue Interest Financing Liability [Text Block]", "documentation": "Revenue interest financing liability." } } }, "auth_ref": [] }, "phat_RevenueInterestLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RevenueInterestLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Revenue interest liability current.", "label": "Revenue Interest Liability Current", "negatedLabel": "Less: current portion" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r737" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 0.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Revenues, Total", "label": "Revenues", "terseLabel": "Product revenue, net", "verboseLabel": "Net product revenues related to sales", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r114", "r131", "r134", "r135", "r171", "r185", "r186", "r207", "r213", "r217", "r219", "r221", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r357", "r531", "r634", "r636", "r822", "r860", "r890", "r891", "r995", "r996", "r1118", "r1140" ] }, "phat_RobertBreedloveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RobertBreedloveMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Robert Breedlove.", "label": "Robert Breedlove [Member]" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Royalty Expense", "terseLabel": "Royalty expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r22" ] }, "phat_RoyaltyPaymentsAndPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "RoyaltyPaymentsAndPayables", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityScheduleOfTotalRevenueInterestFinancingLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty payments and payables.", "label": "Royalty Payments and Payables", "terseLabel": "Less: royalty payments and payables", "negatedLabel": "Less: royalty payments and payables" } } }, "auth_ref": [] }, "phat_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arr Modified Flag", "documentation": "Rule 10b5-1 Arr modified flag.", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r979" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r979" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Common stock, price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "phat_SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare": { "xbrltype": "percentItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SalesCommissionPayableAsAPercentageOfSaleOfGrossSalesPricePerShare", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales commission payable as a percentage of sale of gross sales price per share.", "label": "Sales Commission Payable as a percentage of sale of Gross Sales Price per share", "terseLabel": "Sales commission payable as a percentage of sale of gross sales price per share" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SalesRevenueProductLineMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Product and Service Benchmark [Member]", "terseLabel": "Product Sales", "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [ "r1096", "r1097" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioForecastMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r394" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r64", "r65", "r160", "r394", "r991" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r475" ] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Total Debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r17", "r44", "r45", "r46", "r837", "r839", "r1002", "r1009", "r1010", "r1083", "r1087", "r1146", "r1205", "r1229" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Summary of Stock-Based Compensation Expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Future Minimum Principal Payments Under Term Loans", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]", "terseLabel": "Summary of PSU Activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units." } } }, "auth_ref": [ "r38" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Activity Related to Restructuring Accrual", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [ "r1132", "r1133" ] }, "phat_ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ScheduleOfRevenueInterestFinancingLiabilityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue Interest Financing Liability", "label": "Schedule of Revenue Interest Financing Liability [Table Text Block]", "documentation": "Schedule of revenue interest financing liability." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table]", "documentation": "Disclosure of information about segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r180", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r215" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Table Text Block]", "terseLabel": "Schedule of Segment Reporting Financial Information", "documentation": "Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total." } } }, "auth_ref": [ "r1100", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1109", "r1110", "r1113" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r396", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r432" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r5", "r6", "r37" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Awards", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r41", "r1183" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Summary of Weighted-Average Assumptions Used to Estimate Fair Value of Stock Options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]", "terseLabel": "Summary of Unvested Shares", "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)." } } }, "auth_ref": [ "r1164" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r904" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r906" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r67", "r171", "r180", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r215", "r221", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r261", "r263", "r275", "r280", "r468", "r469", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r818", "r822", "r823", "r831", "r887", "r1232", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r175", "r219", "r220", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637", "r704", "r705", "r706", "r759", "r761", "r764", "r766", "r769", "r771", "r772", "r773", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r790", "r812", "r842", "r844", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r886", "r895", "r1232", "r1234", "r1235", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r183", "r821", "r829" ] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "terseLabel": "Segment reporting, CODM, profit (loss) measure, how used, description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r206", "r818", "r826" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformation1" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting [Text Block]", "documentation": "The entire disclosure for segment reporting." } } }, "auth_ref": [ "r171", "r179", "r180", "r181", "r182", "r184", "r196", "r198", "r199", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r221", "r816", "r819", "r820", "r822", "r824", "r827", "r828" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r180", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r215" ] }, "us-gaap_SegmentReportingOtherItemCompositionDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingOtherItemCompositionDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Composition, Description", "terseLabel": "Segment reporting, other segment item, composition, description", "documentation": "Description of composition of other segment item not separately disclosed." } } }, "auth_ref": [ "r171", "r198", "r199", "r213", "r822" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r216", "r219", "r817", "r818", "r825" ] }, "us-gaap_SellingAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Selling and Marketing Expense", "totalLabel": "Selling and Marketing Expense, Total", "terseLabel": "Sales and marketing", "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r23", "r805", "r806", "r807", "r809", "r1072" ] }, "phat_SellingGeneralAndAdministrativeExpenseRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SellingGeneralAndAdministrativeExpenseRelatedParty", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Selling, general and administrative expense related party.", "label": "Selling, General And Administrative Expense Related Party", "terseLabel": "Selling, General and administrative expenses, related party" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "terseLabel": "Selling, General and Administrative Expenses", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1184" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description", "terseLabel": "Equity plan, description", "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance." } } }, "auth_ref": [ "r399" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "terseLabel": "Number of Stock Units, Forfeited", "negatedLabel": "Number of Stock Units, Forfeited", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Stock awards, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r414" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "PSUs outstanding", "periodStartLabel": "Unvested Beginning Balance", "periodEndLabel": "Unvested Ending Balance", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r411", "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value Per Share, Unvested Beginning Balance", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r411", "r412" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Stock Units, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "terseLabel": "Number of Stock Units, Vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Total fair value of vested", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value Per Share, Vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Assumptions:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r424" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r396", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r432" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum percentage of eligible compensation contributed by participants", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Additional number of shares available for issuance", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1182" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Common stock, shares authorized for issuance", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r852" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r15" ] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAnnualIncrease", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant annual increase.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Annual Increase", "terseLabel": "Number of shares remain available for issuance, annual increase" } } }, "auth_ref": [] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award, options and other than options forfeitures and expirations in period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award, Options and Other Than Options Forfeitures and Expirations in Period", "terseLabel": "Number of awards, cancelled or forfeited", "verboseLabel": "Number of shares, cancelled or forfeited" } } }, "auth_ref": [] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndOtherThanOptionsGrantsInPeriodGross", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award, options and other than options, grants in period gross.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options and Other than Options, Grants In Period Gross", "terseLabel": "Number of awards, granted", "verboseLabel": "Number of shares, granted" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options Outstanding, Options exercisable as of June 30, 2026", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercisable as of June 30, 2026", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic value of stock options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "terseLabel": "Options Outstanding, Options forfeited, expired or cancelled", "negatedLabel": "Options Outstanding, Options forfeited, expired or cancelled", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1159" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "negatedLabel": "Weighted-Average Exercise Price, Options forfeited, expired or cancelled", "terseLabel": "Weighted-Average Exercise Price, Options forfeited, expired or cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1159" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Options Outstanding, Options cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r409", "r998", "r1013", "r1014", "r1147", "r1148" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Stock options, granted", "verboseLabel": "Options Outstanding, Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r407", "r998", "r1013", "r1014", "r1147", "r1148" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Estimated weighted-average fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r417" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Balance", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding, Ending Balance", "periodStartLabel": "Options Outstanding, Beginning Balance", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r403", "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted-Average Exercise Price, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Beginning Balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r403", "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options vested and expected to vest as of June 30, 2026", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options Outstanding, Options vested and expected to vest as of June 30, 2026", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options vested and expected to vest as of June 30, 2026", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "terseLabel": "Annual increase to shares available for issuance percentage of outstanding common stock", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [ "r1182" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation incremental expense", "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r430" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Number of shares issued", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r15" ] }, "phat_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsExercisedAndSharesVested", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award stock options exercised and shares vested.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Stock Options Exercised And Shares Vested", "terseLabel": "Options Outstanding, Options exercised", "negatedLabel": "Options Outstanding, Options exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r424", "r425", "r426" ] }, "phat_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesAndSharesVestedInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangements by share based payment award options exercises and shares vested in period weighted average exercise price.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises And Shares Vested In Period Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options cancelled", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-Average Exercise Price, Options granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r407" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "terseLabel": "First Anniversary", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "phat_ShareBasedPaymentArrangementEmployeeAndNonemployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ShareBasedPaymentArrangementEmployeeAndNonemployeeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement, employee and nonemployee.", "label": "Share Based Payment Arrangement Employee And Nonemployee [Member]", "terseLabel": "Employee and Nonemployee Director" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfWeightedaverageAssumptionsUsedToEstimateFairValueOfStockOptionsGrantedAndEsppAwardsDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r422" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Options exercisable as of June 30, 2026", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Options exercisable as of June 30, 2026", "documentation": "Weighted-average contractual term remaining for vested portion of option outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r15" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted-Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term", "documentation": "Weighted-average contractual term remaining for option award outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r40" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-Average Remaining Contractual Term, Options vested and expected to vest as of June 30, 2026", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r419" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of PSUs vested", "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock." } } }, "auth_ref": [ "r418" ] }, "phat_SharesAggregateRepurchasePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SharesAggregateRepurchasePrice", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares aggregate repurchase price.", "label": "Shares Aggregate Repurchase Price", "terseLabel": "Shares aggregate repurchase price" } } }, "auth_ref": [] }, "phat_SharesIssuedPricePerShareAfterDeductions": { "xbrltype": "perShareItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SharesIssuedPricePerShareAfterDeductions", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Shares issued, price per share after deductions.", "label": "Shares Issued Price Per Share After Deductions", "terseLabel": "Purchase price per share after deducting underwriting discounts and commissions" } } }, "auth_ref": [] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease costs", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r550", "r872" ] }, "phat_SiliconValleyBankTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SiliconValleyBankTermLoanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "SVB term loan.", "label": "Silicon Valley Bank Term Loan [Member]", "terseLabel": "SVB Term Loan" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSegmentInformationScheduleOfSegmentReportingFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r67", "r171", "r180", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r197", "r198", "r199", "r207", "r208", "r209", "r210", "r211", "r213", "r214", "r215", "r221", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r261", "r263", "r275", "r280", "r468", "r469", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r818", "r822", "r823", "r831", "r887", "r1232", "r1234", "r1235", "r1236", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r62", "r63", "r74", "r100", "r101", "r111", "r112", "r113", "r142", "r143", "r144", "r147", "r155", "r157", "r159", "r172", "r224", "r227", "r253", "r254", "r256", "r332", "r346", "r351", "r352", "r353", "r356", "r358", "r360", "r382", "r383", "r387", "r388", "r435", "r452", "r453", "r459", "r460", "r461", "r464", "r473", "r474", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r499", "r503", "r504", "r505", "r506", "r515", "r535", "r536", "r537", "r538", "r539", "r540", "r544", "r563", "r581", "r619", "r620", "r627", "r628", "r641", "r655", "r681", "r682", "r683", "r700", "r754", "r1152" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r175", "r219", "r220", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r634", "r635", "r636", "r637", "r704", "r705", "r706", "r759", "r761", "r764", "r766", "r769", "r771", "r772", "r773", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r784", "r785", "r790", "r812", "r842", "r844", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r886", "r895", "r1232", "r1234", "r1235", "r1237", "r1238", "r1239", "r1240", "r1241", "r1242", "r1243", "r1244", "r1245", "r1246", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257", "r1258", "r1259", "r1271", "r1272" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r74", "r75", "r78", "r79", "r83", "r93", "r95", "r98", "r99", "r100", "r101", "r103", "r142", "r143", "r144", "r172", "r334", "r335", "r337", "r339", "r343", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r363", "r544", "r584", "r619", "r620", "r626", "r627", "r628", "r694", "r701", "r703", "r709", "r710", "r711", "r712", "r713", "r714", "r717", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r737", "r738", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r754", "r794", "r808", "r809", "r896", "r1274" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeLocationBalanceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfIncomeLocationBalanceAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Location, Statement of Income, Balance [Axis]", "documentation": "Information by location in statement of income line item where disaggregated amount is reported." } } }, "auth_ref": [ "r262", "r269", "r274", "r279", "r483", "r484", "r485", "r486", "r523", "r525", "r527", "r532", "r533", "r534", "r676", "r678", "r739", "r788", "r854", "r855", "r861", "r862", "r864", "r869", "r870", "r1186", "r1187", "r1233" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementScenarioAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r64", "r65", "r160", "r394", "r991", "r992" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r66", "r74", "r75", "r78", "r79", "r83", "r93", "r95", "r98", "r99", "r100", "r101", "r103", "r142", "r143", "r144", "r172", "r222", "r334", "r335", "r337", "r339", "r343", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r358", "r359", "r360", "r363", "r544", "r584", "r619", "r620", "r626", "r627", "r628", "r641", "r694", "r701", "r703", "r709", "r710", "r711", "r712", "r713", "r714", "r717", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r737", "r738", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r754", "r794", "r808", "r809", "r896", "r1274" ] }, "phat_SteveBastMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SteveBastMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Steve Bast [Member]", "documentation": "Steve Bast." } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r913", "r923", "r933", "r965" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "ESPP shares issued, shares", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock shares issued", "label": "Shares issued", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net, shares", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r696", "r754", "r767", "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted shares, shares", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from exercises of stock options, shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r408", "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "phat_StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockIssuedDuringPeriodSharesVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Vesting Of Restricted Stock Units And Performance Stock Units, Net Of Employee Tax Obligation", "documentation": "Stock issued during period, shares, vesting of restricted stock units and performance stock units, net of employee tax obligation.", "terseLabel": "Vesting of restricted stock units and performance stock units, net of employee tax obligations, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "ESPP shares issued", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock and pre-funded warrants in connection with the underwritten public offering, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r700", "r754", "r767", "r902", "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted shares", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock from exercises of stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "phat_StockIssuedDuringPeriodValueVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockIssuedDuringPeriodValueVestingOfRestrictedStockUnitsAndPerformanceStockUnitsNetOfEmployeeTaxObligation", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Vesting Of Restricted Stock Units And Performance Stock Units, Net Of Employee Tax Obligation", "documentation": "Stock issued during period, value, vesting of restricted stock units and performance stock units, net of employee tax obligation.", "terseLabel": "Vesting of restricted stock units and performance stock units, net of employee tax obligations" } } }, "auth_ref": [] }, "phat_StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockOptionPerformanceBasedUnitAndRestrictedStockUnitMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock option performance-based unit and restricted stock unit.", "label": "Stock Option Performance-based Unit and Restricted Stock Unit [Member]", "terseLabel": "Stock options, PSUs and RSUs", "verboseLabel": "Stock Options, PSUs and RSUs Outstanding" } } }, "auth_ref": [] }, "phat_StockOptionPerformanceBasedUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockOptionPerformanceBasedUnitMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option Performance Based Awards Outstanding", "label": "Stock Option Performance Based Unit [Member]", "documentation": "Stock Option Performance Based Unit." } } }, "auth_ref": [] }, "phat_StockOptionsAndPerformanceBasedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockOptionsAndPerformanceBasedAwardsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock options and performance-based awards.", "label": "Stock Options And Performance Based Awards [Member]", "terseLabel": "Stock Options and Performance-Based Units Outstanding" } } }, "auth_ref": [] }, "phat_StockOptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockOptionsAndRestrictedStockUnitsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock options and restricted stock units.", "label": "Stock Options and Restricted Stock Units [Member]", "terseLabel": "Stock Options and Restricted Stock Units Outstanding" } } }, "auth_ref": [] }, "phat_StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockOptionsPerformanceStockUnitsAndRestrictedStockUnitsMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options Performance Stock Units and Restricted Stock Units [Member]", "documentation": "Stock options performance stock units and restricted stock units.", "terseLabel": "Stock Options Performance Stock Units and Restricted Stock Units", "verboseLabel": "Stock Options, RSUs nad PSUs" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StockRepurchaseProgramExpirationDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Expiration Date", "terseLabel": "Stock repurchase program expiration date" } } }, "auth_ref": [ "r1152" ] }, "phat_StockRepurchaseProgramExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockRepurchaseProgramExpirationMonthAndYear", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock Repurchase Program Expiration Month and Year", "label": "Stock Repurchase Program Expiration Month and Year", "terseLabel": "Stock repurchase program expiration period" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Authorized, Number of Shares", "terseLabel": "Number of shares authorized to repurchase" } } }, "auth_ref": [ "r1152" ] }, "phat_StockRepurchaseProgramNumberOfSharesRightLapse": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "StockRepurchaseProgramNumberOfSharesRightLapse", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock repurchase program, number of shares right lapse.", "label": "Stock Repurchase Program Number Of Shares Right Lapse", "terseLabel": "Stock repurchase program, number of shares right lapse" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramPeriodInForce1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchaseProgramPeriodInForce1", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Period in Force", "terseLabel": "Stock repurchase program, period in force", "documentation": "Period share may be purchased under authorized share repurchase plan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Number of Shares", "terseLabel": "Remaining number of shares to be repurchased", "documentation": "Number of shares remaining authorized to be purchased under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1152" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Repurchased During Period, Shares", "terseLabel": "Repurchases of shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r697", "r754", "r768", "r998", "r1013", "r1014", "r1145", "r1147", "r1148", "r1150", "r1151", "r1223", "r1224", "r1227", "r1228" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' deficit", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r33", "r719", "r735", "r755", "r756", "r873", "r903", "r1020", "r1082", "r1085", "r1086", "r1118", "r1203", "r1276" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureSubsequentEvent" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r568", "r569" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "phat_SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SummaryOfRevenueAllowancesAndRelatedAccrualsTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Summary of Revenue Allowances and Related Accruals [Table Text Block]", "documentation": "Summary of revenue allowances and related accruals.", "terseLabel": "Summary of Revenue Allowances and Related Accruals" } } }, "auth_ref": [] }, "phat_SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "SummaryOfSupplementalBalanceSheetInformationRelatedToOperatingLeasesTableTextBlock", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureLeaseCommitmentsTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of supplemental balance sheet information related to operating leases.", "label": "Summary Of Supplemental Balance Sheet Information Related To Operating Leases Table [Text Block]", "terseLabel": "Summary of Supplemental Balance Sheet Information Related to the Operating Leases" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r959" ] }, "phat_TakedaLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TakedaLicenseAgreementMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Takeda license agreement.", "label": "Takeda License Agreement [Member]", "terseLabel": "Takeda License", "verboseLabel": "Takeda License Agreement" } } }, "auth_ref": [] }, "phat_TakedaPharmaceuticalCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TakedaPharmaceuticalCompanyLimitedMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Takeda pharmaceutical company limited.", "label": "Takeda Pharmaceutical Company Limited [Member]", "terseLabel": "Takeda" } } }, "auth_ref": [] }, "phat_TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TaxCutsAndJobsActResearchAndDevelopmentExpendituresAmortizationPeriod", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Tax cuts and jobs act, research and development expenditures amortization period.", "label": "Research and development expenditures, amortization period" } } }, "auth_ref": [] }, "phat_TermLoanAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Advance", "documentation": "Term loan advance.", "label": "Term Loan Advance [Member]" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentAfterFebruaryOneTwoThousandTwentyNineButOnOrPriorToJanuaryOneTwoThousandThirtyMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After February One Two Thousand Twenty Nine But on or Prior to January One Two Thousand Thirty [Member]", "documentation": "Term loan advance prepayment after february one two thousand twenty nine but on or prior to january one two thousand thirty,", "terseLabel": "Term Loan Advance Prepayment after February 1, 2029 but on or prior to January 1, 2030" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterJanuaryOneTwoThousandThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentAfterJanuaryOneTwoThousandThirtyMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After January One Two Thousand Thirty [Member]", "documentation": "Term loan advance prepayment after january one two thousand thirty.", "terseLabel": "Term Loan Advance Prepayment after January 1, 2030" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentAfterSeptemberOneTwoThousandTwentySevenButOnOrPriorToFebruaryOneTwoThousandTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentAfterSeptemberOneTwoThousandTwentySevenButOnOrPriorToFebruaryOneTwoThousandTwentyNineMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment After September One Two Thousand Twenty Seven But on or Prior to February One Two Thousand Twenty Nine [Member]", "documentation": "Term loan advance prepayment after september one two thousand twenty seven but on or prior to february one two thousand twenty nine.", "terseLabel": "Term Loan Advance Prepayment after September 1, 2027 but on or prior to February 1, 2029" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterOctoberOneTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentOnOrAfterOctoberOneTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loan Advance Prepayment On Or After October One Two Thousand Twenty Six.", "label": "Term Loan Advance Prepayment On Or After October One Two Thousand Twenty Six [Member]", "terseLabel": "Term Loan Advance Prepayment on or after October 1, 2026" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterTheTwelfthMonthAnniversaryButPriorToTwenty-FourthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentOnOrAfterTheTwelfthMonthAnniversaryButPriorToTwenty-FourthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment on or After the Twelfth Month Anniversary But Prior To Twenty-fourth Month Anniversary Of The Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment on or after the twelfth month anniversary but prior to twenty-fourth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment on or After the twelfth month anniversary but prior to the twenty-fourth month anniversary of the Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentOnOrAfterTheTwenty-FourthMonthAnniversaryButPriorToThirty-SixthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentOnOrAfterTheTwenty-FourthMonthAnniversaryButPriorToThirty-SixthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment on or After the Twenty-fourth Month Anniversary But Prior To Thirty-sixth Month Anniversary Of The Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment on or after the twenty-fourth month anniversary but prior to thirty-sixth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment on or After the Twenty-fourth Month Anniversary But Prior To Thirty-sixth Month Anniversary Of The Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentPriorToOctoberOneTwoThousandTwentySixMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loan Advance Prepayment Prior to October One Two Thousand Twenty Six [Member]", "label": "Term Loan Advance Prepayment Prior to October One Two Thousand Twenty Six [Member]", "terseLabel": "Term Loan Advance Prepayment Prior to October 1, 2026" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToSeptemberTwoThousandTwentySevenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentPriorToSeptemberTwoThousandTwentySevenMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment Prior To September Two Thousand Twenty Seven [Member]", "documentation": "Term loan advance prepayment prior to september two thousand twenty seven.", "terseLabel": "Term Loan Advance Prepayment Prior to September, 2027" } } }, "auth_ref": [] }, "phat_TermLoanAdvancePrepaymentPriorToTwelfthMonthAnniversaryOfTheFifthAmendmentClosingDateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanAdvancePrepaymentPriorToTwelfthMonthAnniversaryOfTheFifthAmendmentClosingDateMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Advance Prepayment Prior to twelfth month anniversary of the Fifth Amendment Closing Date [Member]", "documentation": "Term loan advance prepayment prior to twelfth month anniversary of the fifth amendment closing date.", "terseLabel": "Term Loan Advance Prepayment Prior to Twelfth Month Anniversary of the Fifth Amendment Closing Date" } } }, "auth_ref": [] }, "phat_TermLoanFirstAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanFirstAdvanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loan first advance.", "label": "Term Loan First Advance [Member]", "terseLabel": "Term Loan First Advance" } } }, "auth_ref": [] }, "phat_TermLoanFourAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanFourAdvanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loan Four Advance [Member]", "documentation": "Term Loan Four Advance.", "terseLabel": "Term Loan Four Advance" } } }, "auth_ref": [] }, "phat_TermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "auth_ref": [] }, "phat_TermLoanSecondAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanSecondAdvanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loan Second Advance.", "label": "Term Loan Second Advance [Member]", "terseLabel": "Term Loan Second Advance" } } }, "auth_ref": [] }, "phat_TermLoanThirdAdvanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoanThirdAdvanceMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term Loan Third Advance", "label": "Term Loan Third Advance [Member]", "documentation": "Term loan third advance." } } }, "auth_ref": [] }, "phat_TermLoansAggregateFiveAdditionalTranchesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregateFiveAdditionalTranchesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loans Aggregate Five Additional Tranches.", "label": "Term Loans Aggregate Five Additional Tranches [Member]", "terseLabel": "Term Loans Aggregate Five Additional Tranches" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesFiveMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loans Aggregate Principal Amount Tranches Five.", "label": "Term Loans Aggregate Principal Amount Tranches Five [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Five" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesFourMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loans, aggregate principal amount tranches four.", "label": "Term Loans Aggregate Principal Amount Tranches Four [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Four" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesOneMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loans, aggregate principal amount tranches one.", "label": "Term Loans Aggregate Principal Amount Tranches One [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches One" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesSixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesSixMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term Loans Aggregate Principal Amount Tranches Six.", "label": "Term Loans Aggregate Principal Amount Tranches Six [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Six" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesThreeAndFourMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Term Loans Aggregate Principal Amount Tranches Three and Four [Member]", "documentation": "Term loans aggregate principal amount tranches three and four.", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three and Four" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesThreeMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loans, aggregate principal amount tranches three.", "label": "Term Loans Aggregate Principal Amount Tranches Three [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Three" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalAmountTranchesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalAmountTranchesTwoMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loans, aggregate principal amount tranches two.", "label": "Term Loans Aggregate Principal Amount Tranches Two [Member]", "terseLabel": "Term Loans, Aggregate Principal Amount Tranches Two" } } }, "auth_ref": [] }, "phat_TermLoansAggregatePrincipalFundedAmountTranchesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TermLoansAggregatePrincipalFundedAmountTranchesTwoMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Term loans aggregate principal funded amount tranches two.", "label": "Term Loans Aggregate Principal Funded Amount Tranches Two [Member]", "terseLabel": "Term Loans, Aggregate Principal Funded Amount Tranches Two" } } }, "auth_ref": [] }, "phat_ThreeCustomersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ThreeCustomersMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Three Customers [Member]", "documentation": "Three customers.", "terseLabel": "Three Customers" } } }, "auth_ref": [] }, "phat_ThreeMonthsTrailingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "ThreeMonthsTrailingMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Three Months Trailing.", "label": "Three Months Trailing [Member]", "terseLabel": "Three Months Trailing" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title of Individual" } } }, "auth_ref": [ "r1114", "r1213" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel": "Title of Individual" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r951" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r958" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable, Net", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r1115", "r1116", "r1117" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r978" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r980" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "phat_TrancheExtensionAmendmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TrancheExtensionAmendmentFee", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tranche extension amendment fee", "label": "Tranche extension amendment fee", "documentation": "Tranche extension amendment fee" } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r981" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r982" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r982" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r980" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r980" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r983" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r981" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r619", "r620", "r628", "r1152" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnauditedParenthetical", "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "label": "Treasury Stock, Common, Shares", "terseLabel": "Treasury stock, shares", "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r361", "r362", "r1223", "r1224", "r1228" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedBalanceSheetsUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Treasury stock -19 shares at June 30, 2026 and December 31, 2025", "negatedLabel": "Treasury stock - 19 shares at March 31, 2023 and December 31, 2022, respectively", "label": "Treasury Stock, Common, Value", "terseLabel": "Treasury stock -19 shares at March 31, 2024 and December 31, 2023", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r361", "r362", "r363", "r1014", "r1148", "r1223", "r1224", "r1228" ] }, "phat_TwoThousandNineteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TwoThousandNineteenEquityIncentivePlanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "2019 equity incentive plan.", "label": "Two Thousand Nineteen Equity Incentive Plan [Member]", "terseLabel": "2019 Equity Incentive Plan" } } }, "auth_ref": [] }, "phat_TwoThousandNineteenIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TwoThousandNineteenIncentiveAwardPlanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureStockholdersEquitySummaryOfPsuAndRsusActivityUnderThe2019IncentiveAwardPlanDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen incentive award plan.", "label": "Two Thousand Nineteen Incentive Award Plan [Member]", "terseLabel": "2019 Incentive Award Plan", "verboseLabel": "2019 Incentive Award Plan" } } }, "auth_ref": [] }, "phat_TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TwoThousandTwentyFiveEmploymentInducementIncentiveAwardPlanMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Five Employment Inducement Incentive Award Plan [Member]", "documentation": "Two Thousand Twenty Five Employment Inducement Incentive Award Plan.", "terseLabel": "2025 Employment Inducement Incentive Award Plan", "verboseLabel": "Inducement Plan" } } }, "auth_ref": [] }, "phat_TwoThousandTwentyThreeAtmOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "TwoThousandTwentyThreeAtmOfferingProgramMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty three atm offering program.", "label": "Two Thousand Twenty Three ATM Offering Program [Member]", "terseLabel": "2023 At-the-Market Offering Program" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfAdoptionMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r58", "r59", "r60", "r61", "r62", "r63", "r119", "r120", "r121", "r145", "r146", "r147", "r148", "r149", "r150", "r160", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r330", "r331", "r332", "r333", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r433", "r434", "r435", "r436", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r470", "r471", "r472", "r473", "r474", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r528", "r558", "r559", "r560", "r561", "r562", "r563", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueInterestFinancingLiabilityAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r475" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r116", "r117", "r272", "r273", "r277", "r278", "r807" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Unamortized Debt Issuance Expense", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r977" ] }, "phat_UnvestedSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "UnvestedSharesMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Unvested shares.", "label": "Unvested Shares [Member]", "terseLabel": "Unvested Shares" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureOrganizationBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r49", "r50", "r173", "r176", "r177", "r178", "r634", "r636", "r813" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableRateAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [ "r1002", "r1007", "r1139", "r1192" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableRateDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [ "r1002", "r1007", "r1139", "r1192" ] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VestingAxis", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "terseLabel": "Vesting", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VestingDomain", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "terseLabel": "Vesting", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r1153", "r1154", "r1155", "r1156", "r1157", "r1158", "r1159", "r1160", "r1161", "r1162", "r1163", "r1165", "r1166", "r1167", "r1168", "r1169", "r1170", "r1171", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179" ] }, "phat_VoqueznaProductMember": { "xbrltype": "domainItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "VoqueznaProductMember", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "VOQUEZNA Product [Member]", "label": "VOQUEZNA Product [Member]", "terseLabel": "VOQUEZNA Product [Member]", "verboseLabel": "VOQUEZNA TRIPLE PAK" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r947" ] }, "phat_WarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "WarrantExercised", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Exercised", "documentation": "Warrant exercised .", "terseLabel": "Warrant exercised" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrant liabilities", "verboseLabel": "Initial fair value of warrants", "label": "Fair value of warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1196", "r1197", "r1198" ] }, "phat_WarrantsExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.phathompharma.com/20260630", "localname": "WarrantsExpirationDate", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrants expiration date.", "label": "Warrants Expiration Date", "terseLabel": "Warrants expiration date" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares of common stock outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r162", "r167" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.phathompharma.com/20260630/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average shares of common stock outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r161", "r167" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r945" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "35", "Topic": "720", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-14" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "330", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-3" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-3A" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481108/505-30-30-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2G", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-9" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "184", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r899": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r901": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r902": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r903": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r991": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r992": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-3" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-7" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(m)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(r)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(s)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(t)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(u)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "50", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718-50/tableOfContent" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2C" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2D" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1206": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1207": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1208": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1209": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-2" }, "r1210": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1211": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1212": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1213": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1214": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1215": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1216": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1217": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1218": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1219": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1220": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "905", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4" }, "r1221": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1222": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478482/942-210-50-1" }, "r1223": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r1224": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r1225": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1226": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1227": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1228": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1229": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1230": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1231": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1232": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1233": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1234": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1235": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1236": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1237": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1238": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1239": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1240": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1269": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479032/944-605-50-1" }, "r1270": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1271": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1272": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1273": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1274": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1275": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1276": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1277": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1278": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "810", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1" } } }